Acta Neuropathologica

, Volume 133, Issue 2, pp 223–244 | Cite as

Multiple sclerosis: experimental models and reality

Open Access
Review

Abstract

One of the most frequent statements, provided in different variations in the introduction of experimental studies on multiple sclerosis (MS), is that “Multiple sclerosis is a demyelinating autoimmune disease and experimental autoimmune encephalomyelitis (EAE) is a suitable model to study its pathogenesis”. However, so far, no single experimental model covers the entire spectrum of the clinical, pathological, or immunological features of the disease. Many different models are available, which proved to be highly useful for studying different aspects of inflammation, demyelination, remyelination, and neurodegeneration in the central nervous system. However, the relevance of results from such models for MS pathogenesis has to be critically validated. Current EAE models are mainly based on inflammation, induced by auto-reactive CD4+ T-cells, and these models reflect important aspects of MS. However, pathological data and results from clinical trials in MS indicate that CD8+ T-cells and B-lymphocytes may play an important role in propagating inflammation and tissue damage in established MS. Viral models may reflect key features of MS-like inflammatory demyelination, but are difficult to use due to their very complex pathogenesis, involving direct virus-induced and immune-mediated mechanisms. Furthermore, evidence for a role of viruses in MS pathogenesis is indirect and limited, and an MS-specific virus infection has not been identified so far. Toxic models are highly useful to unravel mechanisms of de- and remyelination, but do not reflect other important aspects of MS pathology and pathogenesis. For all these reasons, it is important to select the right experimental model to answer specific questions in MS research.

Introduction: basic features of MS, which should be mirrored in experimental models

MS is a chronic inflammatory demyelinating disease of the central nervous system (CNS) [91]. In most patients, the disease starts with a phase of relapses and remissions, which may after 10 to 15 years convert into the progressive phase. Ten to fifteen percent of the patients miss the relapsing phase of the disease and develop primary progressive MS [100]. Progressive MS is generally seen in older patients than relapsing remitting MS, suggesting that age-related changes of the brain play some role for the slow and steady increase of neurological disability in this phase [141]. On pathological examination, inflammation consisting of T-cell and B-cell infiltrates is invariably present in the CNS and lesions of MS patients. This is the case not only in the early relapsing, but also in the progressive phase, at least as long as there is evidence for active demyelination and neurodegeneration [53]. The degree of lymphocytic inflammation is higher in early than in late disease stages. The lymphocytic inflammatory infiltrates are dominated by CD8+ T-cells with much lower contribution of CD4+ T-cells and B-cells [24, 53, 62]. Recent results of clinical trials show profound effects of anti-inflammatory therapies, which globally target T- and B-cells or B-cells alone [150, 152], while therapies that specifically address CD4+ T-cell-mediated inflammation show low or even no effect [145, 161]. Whether the effect of B-cell-directed therapies is due to a blockade of B-cell-mediated inflammation alone, to the reduction of antigen presentation for T-cells or to the elimination of Epstein Barr virus infected B-cells as a driver of the chronic inflammatory process is currently unresolved [61]. Overall, however, the data indicate that CD8+ T-cells and/or B-cells may play a more prominent role in disease pathogenesis, when the disease is already established. This, however, does not exclude that CD4+ T-cells are involved in triggering the inflammatory cascade at disease onset, as suggested by recent genetic association studies [72].

The key feature distinguishing MS from other inflammatory diseases of the brain is the widespread primary demyelination, which gives rise to large focal lesions with complete myelin loss and partial sparing of axons (Fig. 1) [91]. This is most impressively seen in subpial demyelinated lesions in the cerebral cortex, which are absolutely specific for MS and were not seen in any other inflammatory condition of the brain [45, 113] (Fig. 1). In addition to demyelination, there is a partial and variable degeneration and loss of axons in the lesions [44, 81]. However, axonal degeneration, nerve cell loss, and dendritic/synaptic injury also occur in many other inflammatory conditions in the brain in the absence of primary demyelination and are, thus, not an MS-specific pathological feature. Active demyelination and neurodegeneration are associated with profound microglia activation and the presence of macrophage-like cells [45, 163]. In active lesions, astrocytes are activated and seem to be involved in the propagation of the inflammatory response and tissue injury [26]. In established chronic lesions, astrocytes form a dense glial scar.
Fig. 1

Distribution of demyelinating lesions in MS and different EAE-based models. The sites of demyelinated lesions were shown in camera lucida drawings of human brain sections, were projected into schemes redrawn after Paxinos and Watson [124] for rat and murine brain sections, or were outlined in optic nerve and spinal cord schemes. Areas of primary demyelination are shown in green, lesions with dominant axonal loss, and secondarily demyelinated areas in blue, and cortical demyelination in brown. Shaded schemes indicate lack of sufficient information for lesion distribution

Inflammation, primary demyelination, and neurodegeneration are the dominant features of both, relapsing and progressive MS (Fig. 1). So far, no qualitative difference in the pathology between these different disease stages has been unequivocally documented. However, the abundance of specific features differs quantitatively [57] and makes the following pathological alterations the most prominent features of progressive MS:
  1. 1.

    Slow expansion of pre-existing demyelinated lesions, while the formation of new white matter plaques with massive inflammation and blood brain barrier damage is sparse [52].

     
  2. 2.

    Progression of axonal degeneration in the plaques and in the normal appearing white matter, the latter in part due to retrograde and anterograde neuronal degeneration and in part related to inflammation in the meninges and the tissue [57]. This is seen in addition to the acute axonal injury in active MS lesions [53].

     
  3. 3.

    Presence of cortical (subpial) demyelinated lesions which are very prominent and may affect up to 90 % of the cortical ribbon [86] (Fig. 1).

     
  4. 4.

    Occurrence of all these changes on the background of a moderate lymphocytic inflammatory reaction associated with profound microglia activation in the lesions and the adjacent white matter [53].

     

Is MS pathology reproduced in conditions of autoimmune encephalomyelitis in humans?

Before any experimental animal model of autoimmune encephalomyelitis has been developed, it was already clear that sensitization of humans with brain tissue or brain cells can be followed by neuroparalytic complications. This was seen as a side effect of anti-rabies vaccination using inactivated viruses insufficiently purified from brain cells or brain tissues which they have been propagated in. A large meta-analysis of data from 150,000 vaccinated individuals published between 1880 and 1928 revealed that neuroparalytic complications occurred in an incidence of about 1 out of 1000, and that affected patients most frequently presented with a clinical disease of acute polyradiculoneuritis or acute disseminated encephalomyelitis (ADEM; [157]). Only few of these patients developed a condition pathologically resembling MS [146, 160] (Fig. 1). We recently had the chance to study a similar case and found a pathological picture, which reflected all changes also seen in acute MS [64] (Fig. 1). The inflammatory infiltrates mainly consisted of B-lymphocytes and lower numbers of CD8+ T-cells and plasma cells, while CD4+ lymphocytes were virtually absent. These data clearly show that an MS-like disease can be induced by auto-sensitization with brain tissue, but there is a fundamental difference to MS. In all patients, disease subsided after the active sensitization process was stopped and there was no single patient, who developed chronic MS [157]. Similarly, in animal studies, it has been shown that the acute or chronic inflammatory demyelinating disease burns out when the peripheral brain antigen depot at the sensitization site has been removed [159]. This suggests that the propagation of chronic (autoimmune?) disease in MS requires stimulation by a persistent trigger within or outside the CNS.

Models of experimental autoimmune encephalomyelitis

Based on the observation of an inflammatory, in part MS-like disease, after auto-sensitization in humans, attempts have been made to reproduce this disease in animal models [11, 135]. In the early phases of this research, immunization was performed with emulsions of brain tissue dissolved in saline. This resulted in a similar disease as described before in humans, albeit only in a fraction of the sensitized animals and after multiple vaccinations over a long time period. To improve reproducibility, strong adjuvants have been introduced into the sensitization protocol, in most cases complete Freund’s adjuvant, which provides a slow liberation of the sensitizing antigen from the inoculum and uses inactivated mycobacteria as a massive immune stimulant [75]. One effect of this adjuvant is that it massively stimulates phagocytic uptake and presentation of antigens and the subsequent activation and expansion of CD4+ T-lymphocytes [20]. Thus, nearly all of the models, which have so far been used, are biased towards a specific immune response mediated by MHC Class II restricted CD4+ T-lymphocytes. The disease induced by this sensitization process has been named experimental autoimmune encephalomyelitis (EAE), which is now one of the most widely used in vivo models to study immunology and brain inflammation. EAE can be induced in all vertebrates tested so far with a different degree of efficacy. Therefore, a widespread spectrum of models with different specific features is now available [1], most commonly using mice, rats, and primates (see below). The enthusiasm for the EAE models in MS research varied over time. In the early stages (1930–1960), the models have been seen as highly useful tools to study MS pathogenesis, but then, limitations became apparent, which indicated that such models are only useful for the investigation of very specific disease-related questions (1960–1990). The introduction of highly reproducible EAE in mice, using myelin oligodendrocyte glycoprotein MOG35–55 peptide for sensitization [111], offered to address questions on molecular disease mechanisms in transgenic and gene knock-out models which were subsequently widely used by the research community. This enthusiasm, however, clouded the fact that mouse models are rather imperfect in mimicking the disease process of MS (see below).

Overall, the EAE models can be classified into different types, which can be used for different specific research questions.

Passive T-cell transfer models

Pioneer work by Phillip Paterson [123] showed that lymphocytes, which were retrieved from the peripheral immune system after sensitization of animals with brain tissue, are able to induce a neuroinflammatory disease in naïve recipients. Formal proof of this observation was provided by Ben Nun, Wekerle, and Cohen [13], who were able to isolate and propagate T-cell lines and clones, specific for myelin basic protein, which triggered an encephalomyelitis in naïve recipient animals after intravenous transfer (Fig. 2). In subsequent studies, these results, originally obtained in Lewis rats, were expanded to other rat and mouse strains and to other CNS antigens, including other myelin, astrocyte, or neuronal proteins [166]. This passive transfer model is particularly useful to study the mechanisms controlling immune surveillance of the CNS, the induction of brain inflammation, and T-cell-mediated inflammatory tissue injury. These studies defined besides many other aspects the conditions, how T-cells are able to enter the CNS [46, 167], what entry routes into the brain and spinal cord they use [9, 133], how important their re-activation state is within the CNS [77, 115], and to what extent the functional polarization of T-cells determines the extent, quality, and distribution of brain inflammation [127]. A major advantage of such passive transfer models is that the T-cells are already raised and expanded, and that the outcome of brain inflammation is not influenced by the afferent arm of specific immune activation in peripheral lymphatic tissue. The major shortcoming of this model is that it is essentially restricted to inflammation, mediated by CD4+ T-lymphocytes. Irrespective of animals, species, or strain, and of the antigen reactivity of the T-cells used, the passive transfer of CD4+ T-cells induces an inflammatory disease of the CNS with some and variable axonal injury but without widespread focal primary demyelination (Fig. 2, Table 1).
Fig. 2

Basic patterns of pathology in different MS Models Part 1. Pure inflammatory models exemplified by passive transfer of CD4+ T-cells directed against myelin basic protein (MBP) in the Lewis rat. Spinal cord with massive inflammation reflected by the presence of perivenous inflammatory cuffs and diffuse infiltration of the tissue by T-cells and macrophages (a H&E; d CD3; e macrophage marker ED1). Sections stained for myelin (b, Luxol fast blue) or axons (c Bielschowsky silver impregnation) do not show demyelination or axonal loss, but there are some axons with accumulation of amyloid precursor protein (f APP), indicating a mild-to-moderate degree of (in part reversible) axonal injury. Models with chronic inflammatory axonopathy leading to focal lesions with secondary demyelination. As an example, spinal cord pathology of a NOD mouse with chronic EAE, 90 days after active sensitization with myelin oligodendrocyte glycoprotein peptide (MOG35–55), is shown. A confluent inflammatory demyelinated lesion is present in the dorsal column of the spinal cord (g H&E, h Luxol fast blue). There is nearly complete axonal loss within the lesion (i, n Bielschowsky silver impregnation); the lesion is infiltrated by a moderate number of T-cells (j, l CD3) and shows a broad rim of activated macrophages at the lesion edges (k Mac3); ongoing tissue destruction is shown by the presence of myelin protein reactive degradation products in macrophages (m PLP) and by the presence of numerous axons with disturbed fast axonal transport (intra-axonal accumulation of amyloid precursor protein; o APP). Chronic EAE in the DA rat 60 days after active immunization with full-length recombinant myelin oligodendrocyte glycoprotein as a model for extensive inflammatory demyelinating disease; profound inflammation (p H&E) and widespread confluent demyelination (q Luxol fast blue), but nearly complete axonal preservation (r Bielschowsky silver impregnation) and pronounced astrogliosis (s GFAP); the areas of active demyelination are highly infiltrated by macrophages (t ED1), but contain only very few T-lymphocytes (u CD3); and myelin sheaths and myelin degradation products in macrophages are decorated by activated complement (v C9neo antigen)

As will be discussed later, such passive transfer experiments can also be performed with Class I MHC restricted CD8+ T-cells. Under these conditions, inflammation is associated with selective destruction of the target cells by cytotoxic T-lymphocytes, which may result in plaque-like demyelination, when the T-cells are directed against an antigen contained in oligodendrocytes [140] (Fig. 1). Similar models for auto-reactive B-cells are currently not available. They would be particularly interesting and important in the light of recent clinical trials in MS patients, showing a profound beneficial effect of peripheral B-cell depletion on the disease course [150].

Passive co-transfer of auto-reactive T-cells and pathogenic auto-antibodies

The intact blood brain barrier restricts diffusion of circulating auto-antibodies into the brain. In addition, auto-antibodies within the brain require immune activation of effector cells and/or the presence of complement factors forming the terminal membrane attack complex to produce tissue damage. One way to overcome this problem is to systemically inject the respective auto-antibody into animals, in which brain inflammation has been induced by passive transfer of auto-reactive encephalitogenic T-cell lines [96]. In this case, the T-cell reaction induces inflammation with activation of macrophages and microglia, and allows the antibody and complement factors to diffuse into the brain or spinal cord at sites of inflammation and blood–brain barrier damage. This paradigm has first been used to test the demyelinating potential of antibodies against myelin oligodendrocyte glycoprotein in vivo [96]. It showed that under these conditions, the inflammatory reaction is associated with widespread primary demyelination, giving rise to demyelinated plaques with close similarities to those seen in MS. This model may also shed light on the controversial discussion on the presence or absence of inflammation in active MS lesions [8] (Table 1). It showed that in the presence of high titers of circulating demyelinating antibodies, a T-cell-mediated inflammatory response in the CNS is absolutely required to trigger the demyelinating lesions, but the number of transferred T-cells, which are necessary to start the disease, can be very low. Within the respective brain lesions, only an extremely small number of T-cells are present, despite very large plaque-like active demyelination [90]. A similar pathological scenario is also seen in chronic models of MOG-induced EAE after active sensitization, when the lesions are triggered by a cooperation of encephalitogenic T-cells and demyelinating antibodies (see below).
Table 1

Models of inflammatory demyelinating diseases: applications and limitations in MS research

Type

Models

Characteristics

Applications

Limitations

CD4+ T-cell mediated inflammation

(1) Transfer of encephalitogenic T-cells [13]

(2) Acute EAE induced by active sensitization with T-cell antigen or epitope [16, 111]

Highly reproducible inflammatory disease of the CNS; Inflammation by T-cells and macrophages

Limited microglia activation

Variable acute axonal injury

Little permanent axonal loss or demyelination

Analysis of molecular mechanism involved in T-cell-mediated brain inflammation

In vivo testing of anti-inflammatory treatments strategies

Only models for different CD4+ T-cell subsets (Th1, Th17 etc.)

Relevance for inflammation in MS patients currently unclear

CD8+ T-cell mediated brain inflammation

(1) Passive Transfer models with:

(a) true autoimmune T-cells [70]

(b) artificial “neo-auto-antigen [116, 140]

(2) Virus induced inflammatory demyelinating diseases [14, 37]

CNS inflammation with CD8+ T-cells, low macrophage recruitment, profound microglia activation

Direct tissue injury induced by cytotoxic T-cells

In active virus models complex interaction between CD4+ and CD8+ T-cell populations

Analysis of molecular mechanisms involved in inflammation and tissue injury induced by Class I MHC restricted T-cells

Analysis of mechanisms of virus clearance from CNS and direct or bystander tissue injury

So far very difficult to handle

High intra-experimental variation;

The dominance of CD8+ T-cells in MS lesions suggests an important role, but evidences for direct CD8+ T-cell cytotoxicity in the pathogenesis of demyelination and neurodegeneration in MS is very limited;

Chronic CD4+ T-cell mediated brain inflammation and inflammatory axonopathy

Chronic relapsing or progressive mouse models after active immunization with CNS antigens;

Most extensive experience in C57BL/6 mice after immunization with MOG35–55 [10, 60, 111]

Inflammation with focal confluent lesions, mainly in the spinal cord;

Lesions with extensive axonal injury and loss and very little primary demyelination

Good model to study mechanisms of axonal injury and to test axono-(neuro-) protective treatment strategies

Value for analysis of primary de- and remyelination limited;

Allows to analyze mechanisms of neurodegeneration induced by CD4+ T-cells and the subsequent macrophage activation;

Mechanisms of neurodegeneration in MS brains are in part different; thus, validation of findings in MS is of critical importance

T-cell and antibody-mediated inflammatory demyelinating diseases

(1) Co-transfer models with encephalitogenic T-cells and demyelinating antibodies [96]

(2) Active sensitization of rats, guinea pigs or primates with MOG1–125 [73, 89, 155, 156]

T-cell-mediated inflammation with macrophage recruitment and activation; demyelination is induced by specific demyelinating antibodies by complement or antibody-dependent cellular cytotoxicity mechanisms;

Extensive primary inflammatory demyelination

The current model with the closest similarity to the pathology of multiple sclerosis (inflammation, plaques of demyelination in white and grey matter; axonal preservation, variable extent of remyelination);

Similar models can be used to test the pathogenicity of other auto-antibodies, such as for instance anti-Aquaporin 4 antibodies in NMO

MS patients in general do not mount a pathogenic auto-antibody response against MOG;

Patients with MOG auto-antibodies have a disease, which is different from MS;

Indirect immunological and neuropathological evidence in MS argues for the presence of a humoral demyelinating (cytotoxic) factor; whether this factor is an auto-antibody or another inflammatory mediator is currently unresolved

Experimental models with inflammatory demyelination and extensive astrocyte injury or loss

(1) Virus models with additional astrocyte infection [14]

(2) Models with very severe innate immunity stimulation (e.g. focal injection of LPS into the white matter [148]

(3) Models with pathogenic auto-antibodies against astrocytes (e.g. NMO models) [25]

(4) Toxic demyelination induced by ethidium bromide [21]

Brain inflammation with severe astrocyte injury and astrocyte loss, associated with oligodendroglia destruction, primary demyelination and axonal preservation; extensive Schwann cell remyelination

Severe astrocyte injury is present in a small subset of acute fulminant MS cases;

Astrocyte injury and loss with secondary demyelination in NMO

Although astrocyte injury is present in some fulminant MS lesions, the mechanism is currently not fully defined; mechanisms identified in the respective models have to be validated regarding the relevance for MS

Viral Models of inflammatory demyelination

Theiler’s virus model [37]

MHV (coronavirus) models [14]

Virus-induced inflammatory demyelinating disease, which in many aspects reflects the disease in MS

These models allow to define the mechanisms, how anti-virus and autoimmune reactions may cooperate in the induction of inflammatory demyelination

Despite extensive search so far, no MS-specific virus infection has been identified;

Disease pathogenesis in these models is highly complex and proved to be difficult to dissect

Toxic Models of demyelination and remyelination

(1) Cuprizone Models [132]

(2) Lysolecitin Model [74]

(3) Ethidium bromide Model [21]

Highly reproducible time course of demyelination and remyelination; well-defined pathophysiological mechanisms of demyelination

Very good models to study basic biology of demyelination and remyelination

Very efficient spontaneous remyelination after cessation of the toxic injury; permanent remyelination failure, as seen in many MS lesions, is only seen in models with prolonged cuprizone intoxication

More recently, this model has also been used to define the pathogenetic potential of other antibodies, such as those directed against neurofascin or against aquaporin 4 [25, 109]. The latter is now an important experimental model for neuromyelitis optica (NMO), which allows to define the pathogenetic role not only of patient-derived anti-aquaporin 4 auto-antibodies, but also the role of aquaporin 4 reactive T-lymphocytes [129, 169]. A limitation of this model for NMO is that it has been so far not possible to raise a stable pathogenetic “true-autoimmune” aquaporin 4 antibody response in rats or mice by active sensitization. In one of the latest attempts, reported by Kurosawa et al. [85], pathogenic murine aquaporin 4-specific antibodies were produced by immunization of aquaporin 4 deficient mice. Thus, experiments are most frequently performed with human antibodies, which induce an anti-human immunoglobulin G response, which may interfere with pathogenetic mechanisms in chronic disease conditions.

Active sensitization models

These models require active immunization with a CNS antigen together with a strong adjuvant (such as for instance complete Freund’s adjuvant, CFA [11, 75]). In mice, this alone is generally not sufficient and additional treatment of the animals with pertussis toxin is necessary [16]. The exact mechanism, how pertussis toxin augments the sensitization process, is still largely unknown. Suggested potential mechanisms are the inhibition of peripheral T-cell anergy induction [76], a suppression of the function of regulatory T-cells [29], an effect on innate immunity [41], or direct effects on the blood brain barrier [99]. The most frequently used active sensitization model is induced in mice by sensitization with the MOG35–55 peptide in CFA [111] (Fig. 1). This model is easy to induce and results in an acute or chronic inflammatory disease in the spinal cord, dependent upon the immunization procedure and the genetic background of the animals. Although this model is most popular for the analysis of molecular disease mechanisms in transgenic mouse strains, it has major limitations as a model for MS. It is a model for an acute or chronic inflammatory encephalopathy with primary axonal injury mediated by auto-reactive MHC Class II restricted CD4+ T-cells [78; 151; 118). Larger lesions are mainly due to massive axonal degeneration with secondary demyelination, while primary demyelination is sparse or absent, a pathological picture that is quite different from that seen in MS (Fig. 2). Another shortcoming of this model is that its pathology is largely confined to the spinal cord, with low affection of the brain stem and the cerebellum and very little inflammation or tissue damage in the forebrain.

A disease, which more closely resembles MS, is induced by active sensitization of rats [156], guinea pigs [89], or primates [73] with the recombinant extracellular domain (amino acids 1–125) of myelin oligodendrocyte glycoprotein (MOG), with myelin or with brain tissue in CFA. The pathogenetic principle in these models is that they induce a CD4+ T-cell-mediated encephalitogenic response together with a demyelinating auto-antibody response against MOG [96]. The pathological hallmark in these models is the appearance of large confluent plaques of primary demyelination with partial axonal sparing, comparable to the lesions seen in MS patients (Figs. 1, 2) [156]. The extent of demyelination and the topographical distribution of the demyelinated lesions depend upon the genetic background of the animals [165]. Thus, in certain rat strains and in primates also, very large (subpial) cortical demyelinated lesions are seen, which are related to a chronic inflammatory process in the meninges [131, 155] (Fig. 1). Overall, these models in many respects resemble the pathological changes in MS, although it has to be considered that anti-MOG antibodies are, in general, not present in the serum of MS patients. When they are found in patients, they are mostly associated with clinical phenotypes, which are distinct from MS, resembling ADEM, aquaporin 4 negative NMO, or an atypical inflammatory demyelinating disease, which does not fulfill the diagnostic criteria for MS [79, 147]. Thus, MOG-induced disease in experimental animals may be a perfect model for a MOG autoimmune syndrome in humans, which may be distinct from MS. In MS, demyelinating and neurotoxic activity have been described in sera and cerebrospinal fluid. Whether this is due to auto-antibodies against so far undefined CNS antigens [23] or to inflammatory mediators other than immunoglobulin [98] is currently unresolved (Table 1).

Spontaneous models of EAE

Diseases, which are induced by passive transfer of T-cells or by active immunization, offer only limited possibilities to identify immunological mechanisms, which are responsible to initiate the disease process or which regulate relapses. To overcome these problems, new models have been created, in which animals develop a spontaneous inflammatory demyelinating disease. This can be done by transgenically expressing a T-cell receptor of encephalitogenic T-cells, which recognizes a brain antigen, such as MOG [17]. These animals are born normal and when kept under the conventional breeding and housing conditions develop a spontaneous inflammatory or inflammatory demyelinating disease several months after birth (Fig. 1), in a frequency of up to 80 %, depending on mouse strain and gender [130]. In addition, such animals can be crossed with B-cell receptor transgenic mice, which mount an auto-reactive (demyelinating) antibody response [18, 83]. However, despite the presence of potentially demyelinating antibodies in these double transgenic mice, primary demyelination in the CNS lesions is sparse in contrast to those in rats or primates with a demyelinating anti-MOG antibody response and no complement activation is seen in the lesions [83]. As in other mouse models, the pathology of the lesions shows preferential axonal loss with secondary demyelination. Thus, mouse complement activation appears to be less efficient in comparison to that of rats, guinea pigs, or primates. This view is also supported by the observation that the induction of lesions in the mouse after focal injections of (human) aquaporin 4 or MOG antibodies requires the simultaneous presence of human complement [138, 139].

Spontaneous EAE models were found particularly useful for research on the role of gut microbiota in the induction of brain inflammation [15]. When such animals are kept under germ free condition, no disease develops. However, disease is triggered when their gut is colonized with the normal gut flora. Such models can be used to identify the bacterial components of the gut flora, which trigger and expand an encephalitogenic T-cell response. Another interesting observation in such a model was, that in SJL mice, but not in C57BL/6 mice, the presence of the transgenic encephalitogenic T-cells may trigger an endogenous demyelinating anti-MOG antibody response [130]. These results help to explain the mechanisms of antigen/epitope spreading in the induction of chronic brain inflammation, which has been shown in several other EAE models before. Overall, however, the same limitation, as discussed before, applies also for these models. They describe CD4+ T-cell-mediated inflammatory processes of the CNS. As in other mouse models, demyelination is mainly following axonal pathology with a little primary demyelination. To what extent findings obtained in these models are relevant for MS has to be shown in studies involving patients.

Humanized EAE models

Species-related differences in the molecular function of proteins are a problem, which require transgenic expression of the respective molecules in experimental animals in vivo. Since myelin proteins are highly conserved between different species, this problem essentially concerns antigen presentation. As an example, T-cells only recognize their respective antigen, when it is processed in antigen presenting cells and presented in the context of major histocompatibility complex (MHC) molecules, which are highly polymorphic and different between vertebrate strains or species. Thus, the determination of the encephalitogenic potential of auto-reactive T-cells, identified in patients, has to be validated in animals, which express the respective human MHC proteins. This can be achieved in humanized mouse models [12, 42]. Respective studies of EAE, induced in human MHC Class I or II transgenic animals, have contributed to define antigenic peptides, which may be encephalitogenic in humans. However, encephalitogenicity is not only regulated by antigen presentation, but also involves antigen processing and the involvement of adhesions molecules and chemokines, necessary for T-cell migration into the CNS. Thus, an ideal experimental design would require multiple transgenic manipulations, in which all the molecules involved in this process are humanized. Similar rules also apply for the validation of any other molecular pathway involved in the pathogenesis of a disease, such as MS. It is obvious that such an approach is highly complicated and technically challenging, and so far, its use in experimental pathogenesis research is very limited.

Models of focal inflammatory demyelinating lesions in the CNS

All the models described above show inflammatory demyelinating lesions, which are dominantly located in the spinal cord. The location of the lesions is randomly distributed with a certain predilection for the lumbar/sacral spinal cord, but for analyzing molecular events in vivo by dual photon laser microscopy or functional changes by electrophysiology, the precise and reproducible localization of the lesion within a specific area of the CNS is required. It has already been shown in the earliest studies on EAE that inflammatory lesions are precipitated into areas of concomitant brain injury, such as direct trauma, thermal injury lesions, or cyanide-induced demyelinating lesions [92, 93]. This has recently been expanded by the observation that inflammation is also precipitated into demyelinated lesions induced by cuprizone [143]. Interestingly, when EAE pathology is precipitated into forebrain lesions, this is associated with less severe spinal cord or brain stem lesions [92]. Thus, the shift of EAE lesions from a site relevant for clinical deficit into a clinically silent area, which may happen after focal injection of a therapeutic agent, such as, for instance, stem cells, into the forebrain may erroneously mimic therapeutic efficacy.

A similar approach has been used by focal stereotactic injection of a small amount of pro-inflammatory cytokines in animals, which are pre-sensitized with MOG1–125. The latter induces an encephalitogenic T-cell response and a demyelinating anti-MOG antibody response in the peripheral immune system of the sensitized animals (Fig. 1). Focal injection of cytokines precipitates inflammatory demyelination at a defined site of the CNS, located around the injection site. As an example, this strategy was used to define, in detail, the cellular events occurring in cortical EAE lesions [54, 112].

Focal CNS injections can also be used for testing the pathogenic potential of inflammatory mediators, which do not sufficiently pass the intact blood brain barrier in normal animals. This has, for instance, been used for testing the pathogenic potential of demyelinating or aquaporin 4 reactive auto-antibodies in vivo and to analyze the effector mechanisms, such as complement activation or antibody-dependent cellular cytotoxicity, in the process of antibody-mediated tissue injury [138, 139, 162].

Using a comparable approach, mechanisms of innate immunity in the pathogenesis of demyelination have been elucidated. Focal injection of lipopolysaccharide into the spinal cord induces a transient inflammatory reaction during the first days after application, which is followed by the formation of focal inflammatory demyelinating lesions after a delay of several days [43, 106]. The latter is associated with profound microglia and macrophage activation, profound alterations of astrocyte function [148], and a mechanism of tissue injury, which involves oxygen radical-mediated cell injury and hypoxia-like cellular damage, thus, reproducing some key features of lesion pathology seen in a subset of multiple sclerosis patients and lesions [38].

EAE models for primary or secondary progressive MS

After active immunization, EAE animals develop either an acute monophasic or a chronic disease, which may last for several months. In the Biozzi ABH mouse, the chronic course may present with relapses or remission [7] or a disease, which has been described as chronic progressive [3, 60]. However, in these models, the chronic disease is not clinically progressive but reflects stable disease on a moderate-to-high level of neurological disability. In an attempt to reproduce the profound axonal and grey matter injury seen in progressive MS, Biozzi mice were sensitized with neurofilament-L [68, 69]. This procedure resulted in an acute or subacute neuroinflammatory disease with severe axonal pathology also targeting the grey matter, apparently mediated by CD4+ T-cells directed against neurofilament. However, also this model did not reproduce the slow progressive disease characteristic for the progressive stage of MS. More recently, it has been shown that a CD4 T-cell-driven autoimmune disease is also induced due to molecular mimicry between myelin oligodendrocyte glycoprotein35–55 and neurofilament-L [84]. Whether, in these models, neurodegeneration is due to direct interaction between auto-reactive T-cells and neurons or by activated microglia is currently unresolved.

Another study analyzed the effect of age in the induction of autoimmune encephalomyelitis in Biozzi mice [125]. This study reports the induction of a primary progressive like disease course, when animals were sensitized with spinal cord homogenate in complete Freund’s adjuvant, although details on the clinical course are not provided in this study. In contrast to the situation in primary progressive MS in humans, this disease was characterized by very prominent T-cell infiltration in the lesions, which exceeded that seen in comparable models of relapsing or secondary progressive disease.

Profound microglia activation is associated with progression of demyelination and neurodegeneration in the brain of MS patients. One attempt to create a model for progressive MS was, thus, to induce EAE in mice with a genetic background of high innate immunity activation. This was achieved using the non-obese diabetic (NOD) mouse strain [10] (Figs. 1, 2). Such animals develop chronic, in part progressive EAE, over a time period of 70 days with an incidence of 90 % [94, 95]. Although these mice have large lesions in the spinal cord, the pathological alterations are not essentially different from those seen in other mouse EAE models (inflammation, dominant axonal injury with secondary demyelination, and little primary demyelination). As in MS, oxidative injury appears to play a major role in chronic tissue injury, shown by the neuroprotective action of anti-oxidant treatment [10].

One hypothesis, explaining neurodegeneration in progressive MS is that inflammation starts a cascade of events in the brain, which leads to ongoing neurodegeneration that becomes independent from the inflammatory process. This question was addressed in the chronic EAE model in Biozzi/ABH mice described above. In this model, inflammation was blocked by tolerization with a CD4 T-cell-depleting monoclonal antibody at different stages of the chronic disease [60]. This study shows effective reduction in the inflammatory response, absence of active demyelination, and increased remyelination in the tolerized animals. Despite these findings, evidence was provided for ongoing and progressive axonal and neuronal degeneration up to 50 days after tolerization [60]. Ongoing axonal and neuronal degeneration was not reflected by a chronic progressive worsening of neurological disease. In this context, one has to consider that after the transection of axons within a focal lesion, Wallerian degeneration and retrograde or anterograde neuronal degeneration take place and this is a very slow process. Thus, the detection of axonal pathology and progressive loss of axons and neurons may merely reflect the late consequences of lesions, which developed during the active phase of the disease, but do not model progressive disease in MS.

Cortical (subpial) demyelination is a key feature of the pathology of progressive MS. It is already seen in the early disease stages [101] but massively increases, when patients develop progressive disease [86] (Fig. 1). Cortical demyelination is associated with neuronal degeneration [102] and this appears to be a major driving force for secondary Wallerian degeneration in the white matter. In fact, diffuse pathology of the white matter in MS patients correlates better with the extent of cortical lesions than with the size, destructiveness, and location of white matter plaques [86]. Thus, cortical pathology appears to be a very important driving force for chronic progressive neurodegeneration in the MS brain. Active cortical demyelination occurs at sites of meningeal inflammation. In patients with severe and aggressive disease, the inflammatory aggregates in the meninges structurally resemble tertiary lymph follicles [102]. The question, thus, arises to what extent meningeal inflammation and subsequent subpial cortical demyelination can be modeled in EAE animals.

In most chronic EAE animals, meningeal inflammation is sparse and cortical demyelination is absent. There are, however, some exceptions. In specific MOG immunized mouse strains, extensive meningeal inflammation with formation of tertiary lymph follicle-like structures is seen. The formation of these follicles is augmented by the expression of podoplanin in Th17 T-cells and in meningeal cells, a molecule which is crucial for the development of secondary lymphoid follicles [126]. However, meningeal inflammation in this mouse model was not followed by MS-like subpial demyelination.

Extensive subpial demyelination, associated with meningeal inflammation, has been found in selected EAE models in rats and primates after active sensitization with MOG1–125 [131, 155] (Fig. 1). More detailed immunopathological studies of such lesions suggest that they are triggered by inflammatory mediators in cooperation with demyelinating antibodies, which, both, are produced in the meningeal inflammatory infiltrates, diffuse into the cortex, and induce demyelination at distant sites in association with microglia activation. A very similar scenario has been suggested to explain the pathogenesis of subpial cortical lesions in MS patients. Active cortical lesions are associated with meningeal inflammation, which, in its most severe form, may reflect inflammatory cell aggregates with features of tertiary lymph follicles. Whether cortical lesions in MS patients are driven by demyelinating auto-antibodies, which have been detected in the cerebrospinal fluid of MS patients [23], or by other so far unidentified inflammatory mediators [98] is currently not clear.

Recently, chronic microglia activation, excessive oxidative stress, mitochondrial injury, and amplification of oxidative stress by iron liberation from degenerating oligodendrocytes have been suggested as a major driving force of demyelination and neurodegeneration in MS, and this mechanism seems to be particularly important in the progressive stage of MS [103]. Similar tissue alterations are, in part, also present in EAE models, but there are major differences in their degree in comparison to MS. Expression of molecules involved in oxygen radical production is prominent in macrophages within the EAE lesions, but in contrast to the human CNS, they are sparse or absent in microglia at the lesion edge of the normal appearing white or grey matter [144]. Axonal degeneration in acute mouse EAE models involves oxidative stress and mitochondrial injury [118], but the widespread mitochondrial injury with deletion of mitochondrially encoded genes, which is a characteristic finding in MS [28, 104], has so far not been seen in EAE. Finally, iron accumulation in myelin and oligodendrocytes occurs in an age-dependent manner in the human brain and iron is liberated into the extracellular space in actively demyelinating MS lesions [59]. In rodents, a limited degree of iron accumulation is seen at the end of the animal’s life span in the basal ganglia, but not in the rest of the brain or the spinal cord, typically targeted by the inflammatory process in EAE, and it is completely absent in young adult animals preferentially used in EAE experiments [144].

For all these reasons, progressive MS is reflected only to a very limited degree in currently available EAE models.

EAE models driven by MHC Class I restricted CD8+ T-cells

The abundance of CD8+ T-cells in MS lesions suggests that these cells may play an important role in the pathogenesis of the disease. So far, however, it proved to be very difficult to induce a pathogenic CD8+ T-cell autoimmune response by active immunization. One observation, which suggests that this may be possible, came from a study, which analyzed, in detail, the immunology and immunopathology of EAE in C57BL/6 mice, induced by sensitization with MOG35–55 [158]. In this study, a prominent MOG-specific CD8+ T-cell response was observed and CD8+ T-cells, although not in a completely pure form, modified brain inflammation after passive transfer. A contribution of MOG-specific CD8+ T-cells to brain inflammation has also been reported in T-cell receptor transgenic animals [2] and in a humanized mouse model [107], (Table 1).

Another approach isolated and propagated auto-reactive CD8+ T-cells from mice, actively sensitized with myelin basic protein, and transferred them into naïve recipients. This induced clinical disease and brain inflammation in the recipient animals [70]. In other studies, foreign antigens (ovalbumin or influenza hemagglutinin) were transgenically expressed in different cells of the CNS and disease was induced by the passive transfer of T-cells from transgenic animals, which express a T-cell receptor directed against the respective pathogenic epitope of ovalbumin or hemagglutinin [27, 116, 140] (Fig. 1). Taken together, these studies show that auto-reactive Class I MHC restricted T-cells can induce brain inflammation without the help of other T-cell populations in the immune repertoire. The studies have further shown that these CD8+ T-cells are cytotoxic and destroy the cells within the CNS, which contain the cognate antigen. In case of CD8+ T-cells recognizing an antigen within oligodendrocytes, this leads to focal plaques of primary demyelination and oligodendrocyte loss, but other models, targeting astrocytes [27] or neurons, are also available [143].

However, transfer of CD8+ T-cells in general requires much higher cell numbers to induce brain inflammation and tissue injury compared with CD4+ T-cells. This may in part be explained by the observation that oligodendrocyte-specific CD8 cells can enter the normal brain and be eliminated by apoptosis in the course of their interaction with normal oligodendrocytes. However, when they enter the inflamed brain, they are cytotoxic [117]. Using humanized transgenic mouse models, it has been shown that CD8+ T-lymphocytes carrying a human T-cell receptor against proteolipid protein, which has been derived from T-lymphocytes of an MS patient, also can induce brain inflammation in vivo [51]. Overall, however, data on the pathogenicity of auto-reactive CD8+ T-cells are limited in comparison to those available for CD4+ cells.

A major unresolved question of experimental MS research is that currently, no models of B-lymphocyte-associated brain inflammation are available. It is not clear, whether B-cells alone may initiate and drive an acute or chronic inflammatory reaction in the CNS, whether they are just secondarily recruited into T-cell-mediated inflammatory foci and in what way they contribute to the induction and propagation of tissue injury, independent from antibodies.

Models of virus-induced inflammatory demyelination

EAE is an autoimmune disease of the CNS, which is induced by active immunization with brain antigens together with potent immune-stimulating adjuvants, by passive transfer of primed T-cells or by transgenic expression of an autoantigen recognizing T-cell receptor. None of these scenarios give clues on how the disease may be triggered in MS patients. It was, thus, interesting to see that certain virus infections in animals may give rise to an inflammatory demyelinating disease with similarities to MS [37]. So far, however, no MS-specific virus infection has been found, although some indirect evidence suggests that infection with Epstein Barr Virus or activation of endogenous retroviruses may play a role in its pathogenesis [4, 120].

Despite the current lack of evidence for an MS-specific virus infection, the study of virus induced experimental models of inflammatory demyelination may provide insights into the basic mechanisms, how such a pathological condition in the brain and spinal cord could be induced or propagated, and such studies may provide additional information on mechanisms of MS-related inflammation, demyelination and neurodegeneration [37]. A major drawback for virus models, however, is their very complex pathogenesis, involving direct virus induced effects, anti-viral immunity, and additional autoimmune mechanisms [37], and the effects of these different pathogenetic components are difficult to dissect. The two most widely used viral MS models are chronic encephalomyelitis induced by the Theiler’s virus or by the MHV corona virus.

Chronic demyelinating encephalomyelitis induced by the Theiler’s virus (TMEV)

The model is induced by the direct intracerebral infection of the animals with the virus. This leads to an acute encephalomyelitis in most infected animals, and disease course and mortality depend upon the virulence of the virus strain used for infection and the genetic ability of the host animals to mount a specific anti-viral T-cell response. Using specific virus strains (BeAn strain or Daniel’s strain) in mice with specific MHC haplotypes (H-2q,r,s,v,f,p), the acute encephalitic phase is followed by a chronic demyelinating disease, which mainly affects the spinal cord [37]. Virus antigen is cleared from the brain, but persists in the spinal cord in oligodendrocytes [136] and macrophages [97]. The spinal cord lesions are characterized by chronic inflammation, the formation of confluent plaques of primary demyelination, a variable extent of axonal injury, and remyelination, the latter dependent upon the genetic background of the mouse strain [19, 137]. Inflammatory infiltrates consist of a mixture of CD4+ and CD8+ T-cells, B-cells, and plasma cells [119, 122]. Active demyelination occurs at sites of microglia activation and macrophage infiltration. Thus, the lesions share essential features with those present in MS (Table 1).

The TMEV model has extensively been used to study the mechanisms of viral clearance from the CNS. It has been shown that in the early stage, the immune response is mainly directed against the virus [114], but that at later stages, additional autoimmune reactions are induced, most likely through the mechanisms of antigen/epitope spreading [121]. The model also made it possible to define the role of different lymphocyte populations in the pathogenic process. While CD8+ T-cells were instrumental for virus clearance together with a virus-specific antibody response, CD4+ T-cells were involved in inflammatory demyelination [114]. In contrast, depletion of CD8+ T-cells reduced chronic disease in parallel with chronic axonal injury and neurodegeneration [67, 134]. A major difference to what is seen in MS is that a B-cell depleting therapy augments the early inflammatory as well as the late inflammatory demyelinating disease, and this was associated with an increase in viral load within the CNS [55]. The complexity of the disease process in the TMEV models is also reflected by the outcome of treatment studies with induced regulatory T-cells [108]. Regulatory T-cells increased disease in the early stage of the disease by suppressing the anti-viral response, but showed a beneficial effect in the late inflammatory demyelinating stage.

Chronic inflammatory demyelinating disease induced by the Mouse Hepatitis (corona) Virus (MHV)

The isolation of MHV from the brain of a paralyzed mouse, presenting with disseminated encephalomyelitis and prominent demyelination [5], suggested that inflammatory demyelinating diseases may be triggered by viral infection. In the subsequent years, MHV-induced demyelinating encephalomyelitis was developed as a major experimental animal model of MS. MHV is a large corona virus, which may induce hepatic, enteric, respiratory, or neurological disease, depending upon the virus strain. Neurological disease occurs after intracranial or nasal infection with a neurovirulent strain [14]. It develops in two phases: the first phase starts within days after infection and results in a virus-induced panencephalitis. When the animals recover from this first phase, a second phase may appear about 4 weeks later, characterized by neuroparalytic disease with inflammatory demyelinating lesions. Virus is largely eliminated from the brain at the end of the first phase, but viral RNA persists within the late lesions throughout the entire disease. The virology of JHM-induced brain disease has recently been summarized in an excellent review [14]. For this reason, we will only discuss some aspects related to the chronic inflammatory demyelinating disease within this chapter.

The pathology of the disease is characterized by chronic inflammation and the formation of confluent plaques of primary demyelination with variable extent of acute axonal injury and axonal loss (Fig. 3). Virus antigen is seen mainly in the acute phase of the disease and is present in multiple different cell types, including macrophages, microglia, astrocytes, oligodendrocytes, and neurons. When the animals recover from the acute phase, virus in the brain is largely cleared, although viral RNA persists in the tissue throughout the chronic demyelinating phase. However, viral protein expression is sparse or undetectable [153]. Inflammatory infiltrates consist of T-lymphocytes and activated macrophages/microglia [154, 168]. Intrathecal production of immunoglobulins also suggests a major contribution of B-cells and plasma cells to the inflammatory process [39]. Various different immune mechanisms contribute to virus clearance from the CNS, including innate immune mechanisms, CD8+ and CD4+ T-cells, and anti-viral antibodies. Originally, it was suggested that demyelination is a result of lytic oligodendrocyte infection [88], but with application of immune-deficient animal models, it became clear that immune-mediated mechanisms may be more important [66]. They include antigen-independent (bystander) destruction of oligodendrocytes by CD8+ T-cells [34, 36] and gamma-delta T-cells [35] or recognition of virus antigen on oligodendrocytes by specific anti-viral antibodies [80] (Table 1). The mechanisms of tissue injury may, however, in part depend upon the genetic background of the animal and the virus strain of MHV. From all these data, there is strong support for the view that the immune mechanisms, which are involved in virus clearance and the induction of inflammatory demyelination, are different. This view is also supported by the finding that treatment of MHV-infected animals with the immunomodulatory drug fingolimod (FTY720) increases disease severity and viral load in the CNS, but reduces the severity of the demyelinating process [22]. Whether the immune-mediated damage is due to a bystander effect of inflammation or to virus-induced autoimmunity is currently not resolved. However, it has been shown that MHV infection may trigger an encephalitogenic T-cell-mediated autoimmune response against myelin basic protein [164] or proteolipid protein [33]. An interesting difference between MHV models and EAE is that the chronic virus-induced inflammatory demyelination is associated with a massive microglia activation, which is seen in the entire brain and spinal cord, and is characterized by expression of oxygen radical producing enzymes in microglia even at the lesion edge and in the normal appearing white matter, and by extensive oxidative injury in active lesions [144]. In addition, profound astrocyte degeneration may be present, possibly due to virus infection of these cells. Astrocyte dysfunction may contribute to the pathogenesis of oligodendrocyte loss and demyelination. As in toxic models of demyelination with profound astrocyte degeneration, such lesions are preferentially repaired by Schwann cell remyelination.
Fig. 3

Basic patterns of pathology in different MS models Part 2. MHV-induced spinal cord pathology as an example for inflammatory demyelinating lesions with extensive oligodendrocyte and astrocyte loss; large confluent demyelinated lesions in the lateral column of the spinal cord with inflammation and tissue edema (a H&E), complete demyelination (b Luxol fast blue), and nearly complete axonal preservation (c, d Bodian silver impregnation), but nearly complete loss of astrocytes (e GFAP); some of the astrocytes at the lesion edge contain virus antigen (f). The cuprizone model as an example for toxic demyelination; large hyper-cellular demyelinating lesion in the corpus callosum after 6 weeks of cuprizone exposure (g H&E). The lesion shows complete demyelination (h Luxol fast blue) and only mild or moderate axonal loss (i, l Bielschowsky silver impregnation); the site of active demyelination is highly infiltrated by macrophages and activated microglia (j Mac3); oligodendrocytes are lost within the areas of active demyelination and only preserved in the areas with intact myelin (k CNPase)

Until recently, JHM infection has been a common threat in laboratory animal (rodent) colonies [65]. Although this most commonly took place with enteric virus strains, which do not affect the CNS, some caution is warranted. In a study on EAE, induced by passive transfer of auto-reactive T-cells, very unusual large and destructive lesions were noted in the spinal cord. This was present in animals with MHV antibodies in the circulation and further virological analysis revealed coronavirus replication in the lesions [32].

One of the major advantages of virus-induced models of inflammatory demyelinating diseases is that they are caused by the infectious process and not by an active sensitization with brain tissue. This may be a more natural process providing information on the etiology of the disease process in humans. However, despite extensive investigations of these models, key aspects have so far remained unresolved. It is likely, but not finally proven, that the chronic inflammatory process in these models is maintained by the persistence of low amounts of virus in the brain, but that the further tissue damage involves adaptive and innate immune mechanisms, different from those responsible for infection control.

Models of toxic demyelination

Primary demyelination is a pathological hallmark, distinguishing MS from other inflammatory diseases of the central nervous system. To identify new therapeutic strategies, targeting de- and remyelination requires in depth knowledge of the mechanisms involved in these processes [50]. Such information can best be obtained in models of toxic demyelination, which are not complicated by changes in the CNS due to inflammatory processes driven by adaptive immunity. The most frequently used model of toxic demyelination is induced by systemic exposure of the animals to cuprizone [56, 132]. Other models include the focal injection of lysolecithin [58, 74] or of ethidium bromide into specific white matter tracts [21]. Research in these models has provided seminal insights into metabolic processes involved in myelin destruction and repair (for review, see: [49, 50, 132], and was important for in vivo imaging of demyelinated lesions by magnetic resonance imaging [128], for determining the neuroprotective effect of remyelination [49], and for testing therapies aimed to promote remyelination (Table 1).

Cuprizone induced de- and remyelination

The basic features of the cuprizone model, including metabolic and inflammatory mechanisms of de- and remyelination, have recently been summarized in detailed and comprehensive review articles [56, 132], and therefore, only some key characteristics related to the value of this model for MS research will be covered here. Cuprizone is a copper chelating drug, which triggers apoptosis in oligodendrocytes and induces demyelination through mechanisms of oxidative injury. The processes of de- and remyelination are further amplified or modified by inflammatory mechanisms, involving microglia and astrocytes [56]. Most models apply cuprizone in C57BL/6 mice for 4 weeks, which induces demyelination followed by rapid and extensive remyelination [63]. However, demyelinating lesions can be induced in many different mouse strains and also in other animal species, such as, for instance, rats, guinea pigs or hamsters [132]. The predictable location in the corpus callosum (Fig. 3) and time course of the lesions in this model provide an excellent background to define the molecular mechanisms promoting de- and remyelination. However, the rapid and extensive spontaneous remyelination after short-term cuprizone exposure imposes limitations for the use as an experimental MS model. Thus, when using this model in the development of new remyelination-promoting therapies, it has to be kept in mind that the respective studies show an acceleration of the remyelinating process, but do not correct for a permanent remyelination failure characteristic of MS lesions particularly in the progressive stage of the disease. However, even when the cuprizone lesions become fully remyelinated, progressive neurodegeneration may ensue. This is reflected by long-term and progressive decline in motor performance of the animals, associated with ongoing axonal injury in (re)myelinated fibers [105].

To overcome the problem of rapid remyelination, a second model has been developed by exposure of animals to cuprizone for 12 weeks. In this model, chronic demyelinated lesions are induced with little remyelination [110]. Impaired remyelination seems to be due to different factors, such as the depletion of the oligodendrocyte progenitor cell population, changes in the focal environment of cytokines involved in proliferation, or differentiation of progenitor cells or factors which inhibit their migration into the lesions [132]. Similar factors have been proposed to explain in part remyelination failure in MS and have also been implicated in age-related decline of the remyelination capacity [40, 149].

Models of focal toxin-induced demyelination

Lysolecithin, injected into white matter tracts of the CNS, induces focal plaques of demyelination due to a direct (detergent) action of the toxin, which damages the lipid membrane-rich myelin sheath [74]. It is a highly reproducible model of primary demyelination, which has the advantage of triggering a focal lesion at a defined location within the CNS. As in other toxic models of demyelination, the phase of myelin destruction is rapidly followed by remyelination, although the speed and degree of remyelination are age-dependent [30, 48]. Age-related insufficiency of remyelination appears to be due to epigenetic control of oligodendrocyte differentiation inhibitors [149], to impairment of the recruitment of different oligodendrocyte progenitor subsets [31], and to insufficiency of macrophages to clear the remyelination-inhibiting myelin debris [82]. These age-related effects on remyelination capacity appear to be highly relevant for remyelination failure in the progressive stage of MS.

Another focal model of demyelination used the focal injection of ethidium bromide into white matter tracts [21]. This leads to degeneration not only of oligodendrocytes but also of astrocytes. With this model, it was shown that oligodendrocyte remyelination requires the presence of astrocytes. When absent, the lesions are repaired by Schwann cells. This may explain the extensive Schwann cell remyelination seen in some patients with neuromyelitis optica [71].

There is no doubt that toxic models provided the major clues for the understanding of molecular mechanisms of de- and remyelination. They showed that remyelination not only improves the function of axons, but also that it is neuroprotective. They also showed that the mechanisms of remyelination are highly complex and require the presence of progenitor cells, which are capable to perform the task, and a finely tuned expression of stimulatory and inhibitory cytokines or growth factors. To determine the extent, to which these factors or mechanisms are relevant for MS requires analysis of respective lesions in the patients and the careful validation of the therapeutic potential of the factors in MS in clinical trials.

Conclusions

Although no single experimental model reproduces all aspects of multiple sclerosis in a single animal disease, a very large spectrum of different models is currently available, which covers individual aspects and mechanisms relevant for disease pathogenesis. The selection of the right model for MS research, thus, largely depends upon the specific question, to be addressed. Regarding testing of new therapeutic strategies, these models may provide proof of principle that the respective approach provides positive effects in vivo, but many treatments tested positively in these experimental models failed in human clinical trials. However, such studies are indispensable to recognize as far as possible potential harmful side effects of new drugs in the inflamed or damaged CNS.

There are, however, key aspects of multiple sclerosis pathology and pathogenesis, including the role of CD8+ T-cells and B-cells, and the mechanisms of demyelination and tissue damage in the progressive stage of MS, which are so far covered in experimental models only to a very limited degree. Thus, as summarized in Table 2, new experimental models have to be developed to address these questions.
Table 2

Future research strategies for experimental multiple sclerosis research

MS-related topic

MS pathology

Suggested strategy

Role of CD8+ T-cells

Major contribution of CD8+ T-cells in the inflammatory process of MS

[24, 53, 62]

(1) Expand knowledge on mechanisms of inflammation and tissue injury in existing models of CD8+ T-cell-mediated brain inflammation

(2) Define mechanisms, how CD8+ T-cell autoimmunity can be induced by active sensitization

Role of B-cells

Therapeutic effect of B-cell depleting therapies

[61, 150, 152]

Create new in vivo models to test the role of B-cells in neuroinflammation

Mechanisms of Demyelination

Presence of a soluble demyelinating (cytotoxic) factor in serum and cerebrospinal fluid of MS patients

[98]

(1) Define the nature of the demyelinating factor in serum and CSF of MS patients beyond anti-MOG antibodies

(2) Define its role in different models of brain inflammation in vivo

Models for progressive MS

MS lesions develop on the background of pro-inflammatory microglia activation seen already in the normal white matter of age matched controls

[53, 144]

(1) Test the effect of different microglia pre-activation in different models of brain inflammation

(a) non-SPF environment

(b) systemic innate immunity activation prior to induction of autoimmune inflammation

(c) genetic models of microglia pre-activation

 

Mitochondrial damage and “virtual” hypoxia play an important role in demyelination and neurodegeneration in MS, being most pronounced in the progressive stage

[103, 104]

(1) Define mechanisms of tissue injury in mitochondrial mutants

(2) Combine models of mitochondrial dysfunction with models of brain inflammation

In addition, strict rules of experimentation have to be followed to achieve definite and reproducible results. This appears to be highly important, since reproducibility of published experimental studies has sometimes been a problem, and many results from such studies have failed to show comparable effects, when tested in patients. Recently guidelines, which set the standard for publication and grant application, have been formulated for EAE research [6], but similar rules also apply for the other models described in this review.

Notes

Acknowledgments

Open access funding provided by Medical University of Vienna. The study was funded by the Austrian Science Fund (FWF), Projects P25240-B24 (MB) and P27744-B27 (HL).

References

  1. 1.
    Alvord EC (1970) Acute disseminated encephalomyelitis and “allergic” neuroencephalopathies. In: Vinken PY, Bruyn GW (eds) Handbook of clinical neurology, vol 9. Elsevier, New York, pp 500–571Google Scholar
  2. 2.
    Anderson AC, Chandvaskar R, Lee DH, Sullivan JM, Solomon A, Rodriguez-Manzanet R, Greve B, Sobel RA, Kuchroo VK (2012) A transgenic model of central nervous system autoimmunity mediated by CD4+ and CD8+ T and B cells. J Immunol 188:2084–2092PubMedPubMedCentralCrossRefGoogle Scholar
  3. 3.
    Anderson JM, Hampton DW, Patani R, Pryce G, Crowther RA, Reynolds RA, Franklin RJ, Giovannoni G, Compston DA, Baker D, Spillantini MG, Chandran S (2008) Abnormally phosphorylated tau is associated with neuronal and axonal loss in experimental autoimmune encephalomyelitis and multiple sclerosis. Brain 131:1736–1748PubMedCrossRefGoogle Scholar
  4. 4.
    Ascherio A, Munger KL (2016) Epidemiology of multiple sclerosis. From risk factor to prevention—an update. Semin Neurol 36:103–114PubMedCrossRefGoogle Scholar
  5. 5.
    Bailey OT, Pappenheimer AM, Sargent F, Cheever MD, Daniels JB (1949) A murine virus (JHM) causing disseminated encephalomyelitis with extensive destruction of myelin. II. Pathology. J Exp Med 90:195–212PubMedPubMedCentralCrossRefGoogle Scholar
  6. 6.
    Baker D, Amor S (2012) Publication guidelines for refereeing and reporting on animal use in experimental autoimmune encephalomyelitis. J Neuroimmunol 242:78–83PubMedCrossRefGoogle Scholar
  7. 7.
    Baker D, O’Neill JK, Gschmeissner SE, Wilcox CE, Butter C, Turk JL (1990) Induction of chronic relapsing experimental allergic encephalomyelitis in Biozzi mice. J Neuroimmunol 28:261–270PubMedCrossRefGoogle Scholar
  8. 8.
    Barnett MH, Prineas JW (2004) Relapsing and remitting multiple sclerosis: pathology of the newly forming lesion. Ann Neurol 55:458–468PubMedCrossRefGoogle Scholar
  9. 9.
    Bartholomäus I, Kawakami N, Odoardi F, Schläger C, Miljkovic D, Ellwart JW, Klinkert WE, Flügel-Koch C, Issekutz TB, Wekerle H, Flügel A (2009) Effector T cell interactions with meningeal vascular structures in nascent autoimmune CNS lesions. Nature 462:94–98PubMedCrossRefGoogle Scholar
  10. 10.
    Basso AS, Frenkel D, Quintana FJ, Costa-Pinto FA, Petrovic-Stojkovic S, Puckett L, Monsonego A, Bar-Shir A, Engel Y, Gozin M, Weiner HL (2008) Reversal of axonal loss and disability in a mouse model of progressive multiple sclerosis. J Clin Invest 118:1532–1543PubMedPubMedCentralCrossRefGoogle Scholar
  11. 11.
    Baxter AG, Hodgkin PD (2002) Activation rules: the two-signal theories of immune activation. Nat Rev Immunol 2:439–446PubMedGoogle Scholar
  12. 12.
    Ben Nun A, Kaushnasky N, Kawakami N, Krishnamoorthy G, Berer K, Liblau R, Hohlfeld R, Wekerle H (2014) From classic to spontaneous and humanized models of multiple sclerosis: impact on understanding pathogenesis and drug development. J Autoimmun 54:33–50PubMedCrossRefGoogle Scholar
  13. 13.
    Ben-Nun A, Wekerle H, Cohen IR (1981) The rapid isolation of clonable antigen-specific T lymphocyte lines capable of mediating autoimmune encephalomyelitis. Eur J Immunol 11:195–199PubMedCrossRefGoogle Scholar
  14. 14.
    Bender SJ, Weiss SR (2010) Pathogenesis of murine coronavirus in the central nervous system. J Neuroimmune Pharmacol 5:336–354PubMedPubMedCentralCrossRefGoogle Scholar
  15. 15.
    Berer K, Mues M, Koutrolos M, Rasbi ZA, Boziki M, Johner C, Wekerle H, Krishnamoorthy G (2011) Commensal microbiota and myelin autoantigen cooperate to trigger autoimmune demyelination. Nature 479:538–541PubMedCrossRefGoogle Scholar
  16. 16.
    Bernard CC (1976) Experimental autoimmune encephalomyelitis in mice: genetic control of susceptibility. J Immunogenet 3:263–274PubMedCrossRefGoogle Scholar
  17. 17.
    Bettelli E, Pagany M, Weiner HL, Linington C, Sobel RA, Kuchroo VK (2003) Myelin oligodendrocyte glycoprotein-specific T cell receptor transgenic mice develop spontaneous autoimmune optic neuritis. J Exp Med 197:1073–1081PubMedPubMedCentralCrossRefGoogle Scholar
  18. 18.
    Bettelli E, Baeten D, Jäger A, Sobel RA, Kuchroo VK (2006) Myelin oligodendrocyte glycoprotein-specific T and B cells cooperate to induce a Devic-like disease in mice. J Clin Invest 116:2393–2402PubMedPubMedCentralCrossRefGoogle Scholar
  19. 19.
    Bieber AJ, Ure DR, Rodriguez M (2005) Genetically dominant spinal cord repair in a murine model of chronic progressive multiple sclerosis. J Neuropath Exp Neurol 64:46–57PubMedCrossRefGoogle Scholar
  20. 20.
    Billiau A, Matthys P (2001) Modes of action of Freund’s adjuvants in experimental models of autoimmune diseases. J Leukocyte Biol 70:849–860PubMedGoogle Scholar
  21. 21.
    Blakemore WF (1982) Ethidium bromide induced demyelination in the spinal cord of the cat. Neuropath Appl Neurobiol 8:365–375CrossRefGoogle Scholar
  22. 22.
    Blanc CA, Rosen H, Lane TE (2014) FTY720 (fingolimod) modulates the severity of viral-induced encephalomyelitis and demyelination. J Neuroinflammation 11:138PubMedPubMedCentralCrossRefGoogle Scholar
  23. 23.
    Blauth K, Soltys J, Matschulat A, Reiter CR, Ritchie A, Baird NLO, Bennett JL, Owens GP (2015) Antibodies produced by clonally expanded plasma cells in multiple sclerosis cerebrospinal fluid cause demyelination of spinal cord explants. Acta Neuropathol 130:765–781PubMedPubMedCentralCrossRefGoogle Scholar
  24. 24.
    Booss J, Esiri MM, Tourtellotte WW, Mason DY (1983) Immunohistological analysis of T lymphocyte subsets in the central nervous system in chronic progressive multiple sclerosis. J Neurol Sci 62:219–232PubMedCrossRefGoogle Scholar
  25. 25.
    Bradl M, Misu T, Takahashi T, Watanabe M, Mader S, Reindl M, Adzemovic M, Bauer J, Berger T, Fujihara K, Itoyama Y, Lassmann H (2009) Neuromyelitis optica: pathogenicity of patient immunoglobulin in vivo. Ann Neurol 66:630–643PubMedCrossRefGoogle Scholar
  26. 26.
    Brosnan CF, Raine CS (2013) The astrocyte in multiple sclerosis revisited. Glia 61:453–465PubMedCrossRefGoogle Scholar
  27. 27.
    Cabarrocas J, Bauer J, Piaggio E, Liblau R, Lassmann H (2003) Effective and selective immune surveillance of the brain by MHC class I-restricted cytotoxic T lymphocytes. Eur J Immunol 33:1174–1182PubMedCrossRefGoogle Scholar
  28. 28.
    Campbell GR, Ziabreva I, Reeve AK, Krishnan KJ, Reynolds R, Howell O, Lassmann H, Turnbull DM, Mahad DF (2010) Mitochondrial DNA deletions and neurodegeneration in multiple sclerosis. Ann Neurol 69:481–492PubMedCrossRefGoogle Scholar
  29. 29.
    Chen X, Winkler-Pickett RT, Carbonetti NH, Ortaldo RJ, Oppenheim HH, Howard OM (2006) Pertussis toxin as an adjuvant suppresses the number and function of CD4+ CD25+ T regulatory cells. Eur J Immunol 36:671–680PubMedPubMedCentralCrossRefGoogle Scholar
  30. 30.
    Crawford AH, Chambers C, Franklin RJ (2013) Remyelination: the true regeneration of the central nervous system. J Comp Pathol 149:242–254PubMedCrossRefGoogle Scholar
  31. 31.
    Crawford AH, Tripathi RB, Richardson WD, Franklin RJ (2016) Developmental origin of oligodendrocyte lineage cells determines response to demyelination and susceptibility to age-associated functional decline. Cell Rep S2211–S47. doi:10.1016/j.celrep.2016.03.069
  32. 32.
    Cross AH, McCarron R, McFarlin DE, Raine CS (1987) Adoptively transferred acute and chronic relapsing autoimmune encephalomyelitis in the PL/J mouse and observations on altered pathology by intercurrent virus infection. Lab Invest 57:499–512PubMedGoogle Scholar
  33. 33.
    Croxford JL, Ercolini AM, Degutes M, Miller SD (2006) Structural requirements for initiation of cross-reactivity and CNS autoimmunity with a PLP139-151 mimic peptide derived from murine hepatitis virus. Eur J Immunol 36:2671–2680PubMedCrossRefGoogle Scholar
  34. 34.
    Dandekar AA, Anghelina D, Perlman S (2004) Bystander CD8 T-cell-mediated demyelination is interferon-gamma-dependent in a coronavirus model of multiple sclerosis. Am J Pathol 164:363–369PubMedPubMedCentralCrossRefGoogle Scholar
  35. 35.
    Dandekar AA, Perlman S (2002) Virus induced demyelination in nude mice is mediated by gamma delta T cells. Am J Pathol 161:1255–1263PubMedPubMedCentralCrossRefGoogle Scholar
  36. 36.
    Dandekar AA, Wu GF, Pewe L, Perlman S (2001) Axonal damage is T cell mediated and occurs concomitantly with demyelination in mice infected with a neurotropic coronavirus. J Virol 75:6115–6120PubMedPubMedCentralCrossRefGoogle Scholar
  37. 37.
    Denic A, Johnson AJ, Bieber AJ, Warrington AE, Rodriguez M, Pirko I (2011) The relevance of animal models in multiple sclerosis research. Pathophysiology 18:21–29PubMedCrossRefGoogle Scholar
  38. 38.
    Desai RA, Davies AL, Tachrount M, Kasti M, Laulund F, Golay X, Smith KJ (2016) Cause and prevention of demyelination in a model of multiple sclerosis. Ann Neurol 79:591–604PubMedPubMedCentralCrossRefGoogle Scholar
  39. 39.
    Dörries R, Watanabe R, Wege H, ter Meulen V (1986) Murine coronavirus-induced encephalomyelitis in rats: analysis of immunoglobulins and virus-specific antibodies in serum and cerebrospinal fluid. J Neuroimmunol 12:131–142PubMedCrossRefGoogle Scholar
  40. 40.
    Doucette JR, Jiao R, Nazarali AJ (2010) Age-related and cuprizone-induced changes in myelin and transcription factor gene expression and in oligodendrocyte cell densities in the rostral corpus callosum of mice. Cell Mol Neurobiol 30:607–629PubMedCrossRefGoogle Scholar
  41. 41.
    Dumas A, Amiable N, de Rivero Vaccari JP, Chae JJ, Keane RW, Lacroix S, Vallieres L (2014) The inflammosome pyrin contributes to pertussis toxin-induced Il-1ß synthesis, neutrophil intravascular crawling and autoimmune encephalomyelitis. PLoS Pathog 10:1004150CrossRefGoogle Scholar
  42. 42.
    Ellmerich S, Takacs K, Mycko M, Waldner H, Wahid F, Boyton RJ, Smith PA, Amor S, Baker D, Hafler DA, Kuchroo VK, Altmann DM (2004) Disease related epitope spread in a humanized T cell receptor transgenic model of multiple sclerosis. Eur J Immunol 34:1839–1848PubMedCrossRefGoogle Scholar
  43. 43.
    Felts PA, Woolston AM, Fernando HB, Asquith S, Gregson NA, Mizzi OJ, Smith KJ (2005) Inflammation and primary demyelination induced by the intraspinal injection of lipopolysaccharide. Brain 128:1649–1666PubMedCrossRefGoogle Scholar
  44. 44.
    Ferguson B, Matyszak MK, Esiri MM, Perry VH (1997) Axonal damage in acute multiple sclerosis lesions. Brain 120:393–399PubMedCrossRefGoogle Scholar
  45. 45.
    Fischer MT, Wimmer I, Hoftberger R, Gerlach S, Haider L, Zrzavy T, Hametner S, Mahad D, Binder CJ, Krumbholz M, Bauer J, Bradl M, Lassmann H (2013) Disease-specific molecular events in cortical multiple sclerosis lesions. Brain 136:1799–1815PubMedPubMedCentralCrossRefGoogle Scholar
  46. 46.
    Flügel A, Berkowicz T, Ritter T, Labeur M, Jenne DE, Li Z, Ellwart JW, Willem M, Lassmann H, Wekerle H (2001) Migratory activity and functional changes of green fluorescent effector cells before and during experimental autoimmune encephalomyelitis. Immunity 14:547–560PubMedCrossRefGoogle Scholar
  47. 47.
    Fog T (1950) Topographic distribution of plaques in the spinal cord in multiple sclerosis. A.M.A. Arch Neurol Psychiat 63:382–414CrossRefGoogle Scholar
  48. 48.
    Franklin RJ, Thao C, Sim FJ (2002) Ageing and CNS remyelination. NeuroReport 13:923–928PubMedCrossRefGoogle Scholar
  49. 49.
    Franklin RJM, ffrench-Constant C, Edgar J, Smith JM (2012) Neuroprotection and repair in multiple sclerosis. Nat Rev Neurol 8:624–634Google Scholar
  50. 50.
    Franklin RJM, Gallo V (2014) The translational biology of remyelination: past, present and future. Glia 62:1905–1915PubMedCrossRefGoogle Scholar
  51. 51.
    Friese MA, Jakobson KB, Friis L, Etzensperger R, Craner MJ, McMahon RM, Jensen LT, Huygelen V, Jones EY, Bell JI, Fugger L (2008) Opposing effects of HLA class I molecules in tuning autoreactive CD8+ T cells in multiple sclerosis. Nat Med 14:1227–1235PubMedCrossRefGoogle Scholar
  52. 52.
    Frischer J, Weigand S, Guo Y, Kale N, Parisi J, Pirko I, Mandrekar J, Bramow S, Metz I, Brück W, Lassmann H, Lucchinetti C (2015) Clinical and pathological insights into the dynamic nature of the white matter multiple sclerosis plaque. Ann Neurol 78:710–721PubMedPubMedCentralCrossRefGoogle Scholar
  53. 53.
    Frischer JM, Bramow S, Dal Bianco A, Lucchinetti CF, Rauschka H, Schmidbauer M, Laursen H, Sorensen PS, Lassmann H (2009) The relation between inflammation and neurodegeneration in multiple sclerosis brains. Brain 132:1175–1189PubMedPubMedCentralCrossRefGoogle Scholar
  54. 54.
    Gardner C, Magliozzi R, Durrenberger PF, Howell OW, Rundle J, Reynolds T (2013) Cortical grey matter demylination can be induced by elevated pro-inflammatory cytokines in the subarachnoid space of MOG-immunized rats. Brain 136:3596–3608PubMedCrossRefGoogle Scholar
  55. 55.
    Gilli F, Li L, Campbell SJ, Anthony DC, Pachner AR (2015) The effect of B-cell depletion in the Theiler’s model of multiple sclerosis. J Neurol Sci 359:40–47PubMedCrossRefGoogle Scholar
  56. 56.
    Gudi V, Gingele S, Skripuletz T, Stangel M (2014) Glial response during cuprizone-induced de- and remyelination in the CNS. Front Cell Neurosci 8:73PubMedPubMedCentralCrossRefGoogle Scholar
  57. 57.
    Haider L, Zrzavy T, Hametner S, Höftberger R, Bagnato F, Grabner G, Trattnig S, Pfeifenbring S, Brück W, Lassmann H (2016) The topograpy of demyelination and neurodegeneration in the multiple sclerosis brain. Brain 139:807–815PubMedPubMedCentralCrossRefGoogle Scholar
  58. 58.
    Hall SM (1972) The effect of injections of lysophosphatidyl choline into white matter of the adult mouse spinal cord. J Cell Sci 10:535–546PubMedGoogle Scholar
  59. 59.
    Hametner S, Wimmer I, Haider L, Pfeifenbring S, Brück W, Lassmann H (2013) Iron and neurodegeneration in the multiple sclerosis brain. Ann Neurol 74:848–861PubMedPubMedCentralCrossRefGoogle Scholar
  60. 60.
    Hampton DW, Serio A, Pryce G, Al-Izki S, Franklin JM, Giovannoni G, Baker D, Chandran S (2013) Neurodegeneration progresses despite complete elimination of clinical relapses in a mouse model of multiple sclerosis. Acta Neuropath Commun 1:84CrossRefGoogle Scholar
  61. 61.
    Hauser SL (2015) The Charcot lecture/beating MS: a story of B cells, with twists and turns. Mult Scler J 21:8–21CrossRefGoogle Scholar
  62. 62.
    Hayashi T, Morimoto C, Burks JS, Kerr C, Hauser SL (1988) Dual-label immunocytochemistry of the active multiple sclerosis lesion: major histocompatibility complex and activation antigens. Ann Neurol 24:523–531PubMedCrossRefGoogle Scholar
  63. 63.
    Hiremath MM, Saito Y, Knapp GW, Ting JP, Suzuki K, Matsushima GK (1998) Microglia/macrophage accumulation during cuprizone-induced demyelination in C57BL/6 mice. J Neuroimmunol 92:38–49CrossRefGoogle Scholar
  64. 64.
    Höftberger R, Leisser M, Bauer J, Lassmann H (2015) Autoimmune encephalitis in humans: how closely does it reflect multiple sclerosis? Acta Neuropathol Commun 3:80PubMedPubMedCentralCrossRefGoogle Scholar
  65. 65.
    Homberger FR, Zhang L, Barthold SW (1998) Prevalence of enterotropic and polytropic mouse hepatitis virus in enzootically infected mouse colonies. Lab Anim Sci 48:50–54PubMedGoogle Scholar
  66. 66.
    Houtman JJ, Fleming JO (1996) Pathogenesis of mouse hepatitis virus-induced demyelination. J Neurovirol 2:361–376PubMedCrossRefGoogle Scholar
  67. 67.
    Howe CL, Adelson JD, Rodriguez M (2007) Absence of perforin expression confers axonal protection despite demyelination. Neurobiol Dis 25:354–359PubMedCrossRefGoogle Scholar
  68. 68.
    Huizinga R, Heijmans N, Schubert P, Gschmeissner S, t Hart BA, Herrmann H, Amor S (2007) Immunization with neurofilament light protein induces spastic paresis and axonal degeneration in Biozzi ABH mice. J Neuropath Exp Neurol 66:295–304Google Scholar
  69. 69.
    Huizinga R, Gerritsen W, Heijmans N, Amor S (2008) Axonal loss and gray matter pathology as a direct result of autoimmunity to neurofilaments. Neurobiol Dis 32:461–470PubMedCrossRefGoogle Scholar
  70. 70.
    Huseby ES, Liggitt D, Brabb T, Schnabel B, Ohlen C, Goverman J (2001) A pathogenic role for myelin specific CD8(+) T cells in a model for multiple sclerosis. J Exp Med 194:669–676PubMedPubMedCentralCrossRefGoogle Scholar
  71. 71.
    Ikota H, Iwasaki A, Kawarai M, Nakazato Y (2010) Neuromyelitis optica with intraspinal expansion of Schwann cell remyelination. Neuropathology 30:427–433PubMedCrossRefGoogle Scholar
  72. 72.
    International Multiple Sclerosis Genetics Consortium (2013) Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis. Nat Genet 45:1353–1360CrossRefGoogle Scholar
  73. 73.
    Jagessar S, Heijmans N, Blezer E, Bauer J, Weissert R, ‘t Hart B (2015) Immune profile of an atypical EAE model in marmoset monkeys immunized with recombinant human myelin oligodendrocyte glycoprotein in incomplete Freund’s adjuvant. J Neuroinflamm 12:169Google Scholar
  74. 74.
    Jeffery ND, Blakemoore WF (1995) Remyelination of mouse spinal cord axons demyelinated by local injection of lysolecithin. J Neurocytol 24:775–781PubMedCrossRefGoogle Scholar
  75. 75.
    Kabat EA, Wolf A, Bezer AE, Murray JP (1951) Studies on acute disseminated encephalomyelitis produced experimentally in rhesus monkeys. J Exp Med 93:615–633PubMedPubMedCentralCrossRefGoogle Scholar
  76. 76.
    Kamradt T, Soloway PD, Perkins DL, Gefter ML (1991) Pertussis toxin prevents the induction of peripheral T cell anergy and enhances the T cell response to an encephalitogenic peptide of myelin basic protein. J Immunol 147:3296–3302PubMedGoogle Scholar
  77. 77.
    Kawakami N, Nägerl UV, Odoardi F, Bonhoeffer T. Wekerle H, Flügel A (2005) Live imaging of effector cell trafficking and autoantigen recognition within unfolding autoimmune encephalomyelitis lesions. J Exp Med 201:1805–1814Google Scholar
  78. 78.
    Kim JH, Budde MD, Liang HF, Klein RS, Russell JH, Cross AH, Song SK (2006) Detecting axon damage in spinal cord from a mouse model of multiple sclerosis. Neurobiol Dis 21:626–632PubMedCrossRefGoogle Scholar
  79. 79.
    Kim SM, Woodhall MR, Kim JS, Kim SJ, Park KS, Vincent A, Lee KW, Waters P (2015) Antibodies to MOG in adults with inflammatory demyelinating disease. Neurol Neuroimmunol Neuroinflamm 2:e163PubMedPubMedCentralCrossRefGoogle Scholar
  80. 80.
    Kim TS, Perlman S (2005) Virus-specific antibody, in the absence of T cells, mediates demyelination in mice infected with a neurotropic coronavirus. Am J Path 166:801–810PubMedPubMedCentralCrossRefGoogle Scholar
  81. 81.
    Kornek B, Storch MK, Weissert R, Wallstroem E, Stefferl A, Olsson T, Linington C, Schmidbauer M, Lassmann H (2000) Multiple sclerosis and chronic autoimmune encephalomyelitis: a comparative quantitative study of axonal injury in active, inactive, and remyelinated lesions. Am J Pathol 157:267–276PubMedPubMedCentralCrossRefGoogle Scholar
  82. 82.
    Kotter MR, Setzu A, Sim FJ, Van Rooijen N, Franklin RJ (2001) Macrophage depletion impairs oligodendrocyte remyelination following lysolecithin-induced demyelination. Glia 35:204–212PubMedCrossRefGoogle Scholar
  83. 83.
    Krishnamoorthy G, Lassmann H, Wekerle H, Holz A (2006) Spontaneous opticospinal encephalomyelitis in a double-transgenic mouse model of autoimmune T cell/B cell cooperation. J Clin Invest 116:2385–2392PubMedPubMedCentralCrossRefGoogle Scholar
  84. 84.
    Krishnamoorthy G, Saxena A, Mars LT, Domingues HS, Mentele R, Ben-Nun A, Lassmann H, Dornmair K, Kurschus FC, Liblau RS, Wekerle H (2009) Myelin-specific T cells also recognize neuronal autoantigen in a transgenic mouse model of multiple sclerosis. Nat Med 15:626–632PubMedCrossRefGoogle Scholar
  85. 85.
    Kurosawa K, Misu T, Takai Y, Sato DK, Takahashi T, Abe Y, Iwanari H, Ogawa R, Nakashima I, Fujihara K, Hamakubo T, Yasui M, Aoki M (2015) Severely exacerbated neuromyelitis optica rat model with extensive astrocytopathy by high affinity anti-aquaporin-4 monoclonal antibody. Acta Neuropathol Commun 3:82PubMedPubMedCentralCrossRefGoogle Scholar
  86. 86.
    Kutzelnigg A, Lucchinetti CF, Stadelmann C, Brück W, Rauschka H, Bergmann M, Schmidbauer M, Parisi JE, Lassmann H (2005) Cortical demyelination and diffuse white matter injury in multiple sclerosis. Brain 128:2705–2712PubMedCrossRefGoogle Scholar
  87. 87.
    Kutzelnigg A, Faber-Rod JC, Bauer J, Lucchinetti CF, Sorensen PS, Laursen H, Stadelmann C, Brück W, Rauschka H, Schmidbauer M, Lassmann H (2007) Widespread demyelination in the cerebellar cortex in multiple sclerosis. Brain Pathol 17:38–44PubMedCrossRefGoogle Scholar
  88. 88.
    Lampert PW, Sims JK, Kniazeff AJ (1973) Mechanisms of demyelination in JHM virus encephalomyelitis. Acta Neuropathol 24:76–85PubMedCrossRefGoogle Scholar
  89. 89.
    Lassmann H, Wisniewski HM (1979) Chronic relapsing experimental allergic encephalomyelitis: clinico-pathological comparison with multiple sclerosis. Arch Neurol 36:490–497PubMedCrossRefGoogle Scholar
  90. 90.
    Lassmann H, Brunner C, Bradl M, Linington C (1988) Experimental allergic encephalomyelitis: the balance between encephalitogenic T lymphocytes and demyelinating antibodies determines size and structure of demyelinated lesions. Acta Neuropathol 75:566–576PubMedCrossRefGoogle Scholar
  91. 91.
    Lassmann H, Brück W, Lucchinetti C (2007) The immunopathology of multiple sclerosis: an overview. Brain Pathol 17:210–218PubMedCrossRefGoogle Scholar
  92. 92.
    Levine S (1960) Localization of allergic encephalomyelitis in lesions of cyanide encephalopathy. J Neuropath Exp Neurol 19:238–247PubMedCrossRefGoogle Scholar
  93. 93.
    Levine S, Hoenig EM (1968) Induced localization of allergic adrenalitis and encephalomyelitis at sites of thermal injury. J Immunol 100:1310–1318PubMedGoogle Scholar
  94. 94.
    Levy H, Assaf D, Frenkel D (2010) Characterization of brain lesions in a mouse model of progressive multiple sclerosis. Exp Neurol 226:148–158PubMedCrossRefGoogle Scholar
  95. 95.
    Levy Barazany H, Barazany D, Puckett L, Blanga-Kanfi S, Borenstein-Auerbach N, Yang K, Peron JP, Weiner HL, Frenkel D (2014) Brain MRI of nasal MOG therapeutic effect in relapsing-progressive EAE. Exp Neurol 255:63–70PubMedCrossRefGoogle Scholar
  96. 96.
    Linington C, Bradl M, Lassmann H, Brunner C, Vass K (1988) Augmentation of demyelination in rat acute allergic encephalomyelitis by circulating mouse monoclonal antibodies directed against a myelin/oligodendrocyte glycoprotein. Am J Pathol 130:443–454PubMedPubMedCentralGoogle Scholar
  97. 97.
    Lipton HL, Twaddle G, Jelachich ML (1995) The predominant virus antigen burden is in macrophages in Theiler’s murine encephalomyelitis virus-induced demyelinating disease. J Virol 69:2525–2533PubMedPubMedCentralGoogle Scholar
  98. 98.
    Lisak RP, Benjamins JA, Nedelkoska L, Barger JL, Ragheb S, Fan B, Ouamara N, Johnson TA, Rajasekharan S, Bar-Or A (2012) Secretory products of multiple sclerosis B-cells are cytotoxic to oligodendrocytes in vitro. J Neuroimmunol 246:85–95PubMedCrossRefGoogle Scholar
  99. 99.
    Lu C, Pelech S, Zhang H, Bond J, Spach K, Noubade R, Blanjenhorn EP, Teuscher C (2008) Pertussis toxin induces angiogenesis in brain microvascular endothelial cells. J Neurosci Res 86:2624–2640PubMedCrossRefGoogle Scholar
  100. 100.
    Lublin FD, Reingold SC (1996) Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 46:907–911PubMedCrossRefGoogle Scholar
  101. 101.
    Lucchinetti CF, Popescu BF, Bunyan RF, Moll NM, Roemer SF, Lassmann H, Brück W, Parisi JE, Scheithauer BW, Giannini C, Weigand SD, Mandrekar J, Ransohoff RM (2011) Inflammatory cortical demyelination in early multiple sclerosis. N Engl J Med 365:2188–2197PubMedPubMedCentralCrossRefGoogle Scholar
  102. 102.
    Magliozzi R, Howell OW, Reeves C, Roncaroli F, Nicholas R, Serafini B, Aloisi F, Reynolds R (2010) A Gradient of neuronal loss and meningeal inflammation in multiple sclerosis. Ann Neurol 68:477–493PubMedCrossRefGoogle Scholar
  103. 103.
    Mahad DH, Trapp BD, Lassmann H (2015) Pathological mechanisms in progressive multiple sclerosis. Lancet Neurol 14:183–193PubMedCrossRefGoogle Scholar
  104. 104.
    Mahad D, Ziabreva I, Lassmann H, Turnbull D (2008) Mitochondrial defects in acute multiple sclerosis lesions. Brain 131:1722–1735PubMedPubMedCentralCrossRefGoogle Scholar
  105. 105.
    Manrique-Hoyos N, Jürgens T, Gronborg M, Kreutzfeldt M, Schedensack M, Kuhlmann T, Schrick C, Brück W, Urlaub H, Simons M, Merkler D (2012) Late motor decline after accomplished remyelination: impact for progressive multiple sclerosis. Ann Neurol 71:227–244PubMedCrossRefGoogle Scholar
  106. 106.
    Marik C, Felts PA, Bauer J, Lassmann H, Smith KJ (2007) Lesion genesis in a subset of patients with multiple sclerosis: a role for innate immunity? Brain 130:2800–2815PubMedPubMedCentralCrossRefGoogle Scholar
  107. 107.
    Mars LT, Bauer J, Gross DA, Bucciarelli F, Firat H, Hudrisier D, Lemonnier F, Kosmatopoulos K, Liblau RS (2007) CD8 T cell response to myelin oligodendrocyte glycoprotein-derived peptides in humanized HLA-A*0201-transgenic mice. J Immunol 179:5090–5098PubMedCrossRefGoogle Scholar
  108. 108.
    Martinez NE, Karlsson F, Sato F, Kawai E, Omura S, Minagar A, Grisham MB, Tsunoda I (2014) Protective and detrimental roles for regulatory T cells in a viral model for multiple sclerosis. Brain Pathol 24:436–451PubMedPubMedCentralCrossRefGoogle Scholar
  109. 109.
    Mathey EK, Derfuss T, Storch MK, Williams KR, Hales K, Woolley DR, Al-Hayani A, Davies SN, Rasband MN, Olsson T, Moldenhauer A, Velhin S, Hohlfeld R, Meinl E, Linington C (2007) Neurofascin as a novel target for autoantibody-mediated axonal injury. J Exp Med 204:2363–2372PubMedPubMedCentralCrossRefGoogle Scholar
  110. 110.
    Matsushima GK, Morell P (2001) The neurotoxicant cuprizone, as a model to study demyelination and remyelination in the central nervous system. Brain Pathol 11:107–116PubMedCrossRefGoogle Scholar
  111. 111.
    Mendel I, Kerlero de Rosbo N, Ben Nun A (1995) A myelin oligodendrocyte glycoprotein peptide induces typical chronic experimental autoimmune encephalomyelitis in H-2b mice: fine specificity and T cell receptor V beta expression of encephalitogenic cells. Eur J Immunol 25:1951–1959PubMedCrossRefGoogle Scholar
  112. 112.
    Merkler D, Ernsting T, Kerschensteiner M, Brück W, Stadelmann C (2006) A new focal EAE model of cortical demyelination: multiple sclerosis-like lesions with rapid resolution of inflammation and extensive remyelination. Brain 129:1972–1983PubMedCrossRefGoogle Scholar
  113. 113.
    Moll NM, Rietsch AM, Ransohoff AJ, Cossoy MB, Huang D, Eichler FS, Trapp BD, Ransohoff RM (2008) Cortical demyelination in PML and MS: similarities and differences. Neurology 70:336–343PubMedCrossRefGoogle Scholar
  114. 114.
    Monteyne P, Bureau JF, Brahic M (1997) The infection of mouse by Theiler’s virus: from genetics to immunology. Immunol Rev 159:163–176PubMedCrossRefGoogle Scholar
  115. 115.
    Mues M, Bartholomäus I, Thestrup T, Griesbeck O, Wekerle H, Kawakami N, Krishnamoorthy G (2013) Real-time in vivo analysis of T cell activation in the central nervous system using genetically encoded calcium indicator. Nat Med 19:778–783PubMedCrossRefGoogle Scholar
  116. 116.
    Na SY, Cao Y, Toben C, Nitschke L, Stadelmann C, Gold R, Schimpl A, Hünig T (2008) Naive CD8 T-cells initiate spontaneous autoimmunity to a sequestered model antigen of the central nervous system. Brain 131:2353–2365PubMedCrossRefGoogle Scholar
  117. 117.
    Na SY, Hermann A, Sanchez-Ruiz M, Storch A, Deckert M, Hünig T (2012) Oligodendrocytes enforce immune tolerance of the uninfected brain by purging the peripheral repertoire of autoreactive CD8+ T cells. Immunity 37:134–146PubMedCrossRefGoogle Scholar
  118. 118.
    Nikic I, Merkler D, Sorbara C, Brinkoetter M, Kreutzfeldt M, Bareyre FM, Brück W, Bishop D, Misgeld T, Kerschensteiner M (2011) A reversible form of axon damage in experimental autoimmune encephalomyelitis and multiple sclerosis. Nat Med 17:495–499PubMedCrossRefGoogle Scholar
  119. 119.
    Njenga MK, Coenen MJ, DeCuir N, Yeh HY, Rodriguez M (2000) Short term treatment with interferon-alpha/beta promotes remyelination, whereas long term treatment aggravates demyelination in a murine model of multiple sclerosis. J Neurosci Res 59:661–670PubMedCrossRefGoogle Scholar
  120. 120.
    Nexo BA, Jensen SB, Nissen KK, Hansen B, Laska MJ (2016) Two endogenous retroviral loci appear to contribute to multiple sclerosis. BMC Neurol 16:57PubMedPubMedCentralCrossRefGoogle Scholar
  121. 121.
    Olson JK, Eagar TN, Miller SD (2002) Functional activation of myelin-specific T cells by virus-induced molecular mimicry. J Immunol 169:2719–2726PubMedCrossRefGoogle Scholar
  122. 122.
    Pachner AR, Li L, Lagunoff D (2011) Plasma cells in the central nervous system in the Theiler’s virus model of multiple sclerosis. J Neuroimmunol 232:35–40PubMedCrossRefGoogle Scholar
  123. 123.
    Paterson PY (1960) Transfer of allergic encephalomyelitis in rats by means of lymph node cells. J Exp Med 111:119–135PubMedPubMedCentralCrossRefGoogle Scholar
  124. 124.
    Paxinos G, Watson C (1998) The rat brain in stereotaxic coordinates, 4th edn. Academic, San DiegoGoogle Scholar
  125. 125.
    Peferoen LAN, Breur M, van de Berg S, Peferoen-Baert R, Boddeke EHWGM, van der Valk P, Pryce G, van Noort JM, Baker D, Amor S (2016) Ageing and recurrent episodes of neuroinflammation promote progressive EAE in Biozzi mice. Immunology 149:146–156PubMedCrossRefGoogle Scholar
  126. 126.
    Peters A, Pitcher LA, Sullivan JM, Mitsdoerffer M, Acton SE, Franz B, Wucherpfennig K, Turley S, Carroll MC, Sobel RA, Bettelli E, Kuchroo VK (2011) Th17 cells induce ectopic lymphoid follicles in central nervous system tissue inflammation. Immunity 35:986–996PubMedPubMedCentralCrossRefGoogle Scholar
  127. 127.
    Pierson E, Simmons SB, Castelli L, Goverman JM (2012) Mechanisms regulating regional localization of inflammation during CNS autoimmunity. Immunol Rev 248:205–215PubMedPubMedCentralCrossRefGoogle Scholar
  128. 128.
    Pirko I, Johnson AJ (2008) Neuroimaging of demyelination and remyelination models. Curr Top Microbiol Immunol 318:241–266PubMedGoogle Scholar
  129. 129.
    Pohl M, Kawakami N, Kitic M, Bauer J, Martins R, Fischer MT, Machado-Santos J, Mader S, Ellwart JW, Misu T, Fujihara K, Wekerle H, Reindl M, Lassmann H, Bradl M (2013) T cell-activation in neuromyelitis optica lesions plays a role in their formation. Acta Neuropathol Commun 1:85PubMedPubMedCentralCrossRefGoogle Scholar
  130. 130.
    Pöllinger B, Krishnamoorthy G, Berer K, Lassmann H, Bösl MR, Dunn R, Domingues HS, Holz A, Kurschus FC, Wekerle H (2009) Spontaneous relapsing-remitting EAE in the SJL/J mouse: MOG reactive transgenic T cells recruit endogeneous MOG-specific B cells. J Exp Med 206:1303–1316PubMedPubMedCentralCrossRefGoogle Scholar
  131. 131.
    Pomeroy IM, Matthews PM, Frank JA, Jordan EK, Esiri MM (2005) Demyelinated neocortical lesions in marmoset autoimmune encephalomyelitis mimic those in multiple sclerosis. Brain 128:2713–2721PubMedCrossRefGoogle Scholar
  132. 132.
    Praet J, Guglielmetti C, Berneman Z, Van der Linden A, Ponsaerts P (2014) Cellular and molecular neuropathology of the cuprizone mouse model: clinical relevance for multiple sclerosis. Neurosci Behav Rev 47:485–505CrossRefGoogle Scholar
  133. 133.
    Reboldi A, Coisne C, Baumjohann D, Benvenuto F, Bottinelli D, Lira S, Uccelli A, Lanzavecchia A, Engelhardt B, Sallusto F (2009) C-C chemokine receptor-6 regulated entry of TH-17 cells into the CNS through the choroid plexus is required for the induction of EAE. Nat Immunol 10:514–523PubMedCrossRefGoogle Scholar
  134. 134.
    Rivera-Quinones C, McGavern D, Schmelzer JD, Hunter SF, Low PA, Rodriguez M (1998) Absence of neurological deficits following extensive demyelination in a class I-deficient murine model of multiple sclerosis. Nat Med 4:187–193PubMedCrossRefGoogle Scholar
  135. 135.
    Rivers TM, Sprunt DH, Berry GP (1933) Observations on attempts to produce acute disseminated encephalomyelitis in monkeys. J Exp Med 58:39–53PubMedPubMedCentralCrossRefGoogle Scholar
  136. 136.
    Rodriguez M, Leibowitz JL, Lampert PW (1983) Persistent infection of oligodendrocytes in Theiler’s virus-induced encephalomyelitis. Ann Neurol 13:426–433PubMedCrossRefGoogle Scholar
  137. 137.
    Rodriguez M, Oleszak E, Leibowitz J (1987) Theiler’s murine encephalomyelitis: a model of demyelination and persistence of virus. Crit Rev Immunol 7:325–365PubMedGoogle Scholar
  138. 138.
    Saadoun S, Waters P, Bell BA, Vincent A, Verkman AS, Papadopoulos MC (2010) Intra-cerebral injection of neuromyelitis optica immunoglobulin G and human complement produces neuromyelitis optica lesions in mice. Brain 133:349–361PubMedPubMedCentralCrossRefGoogle Scholar
  139. 139.
    Saadoun S, Waters P, Owens GP, Bennett JL, Vincent A, Papadopoulos MC (2014) Neuromyelitis optica MOG-IgG causes reversible lesions in the mouse brain. Acta Neuropath Commun 2:35CrossRefGoogle Scholar
  140. 140.
    Saxena A, Bauer J, Scheikl T, Zappulla J, Audebert M, Desbois S, Waisman A, Lassmann H, Liblau RS, Mars LT (2008) Cutting edge: multiple sclerosis-like lesions induced by effector CD8 T cells recognizing a sequestered antigen on oligodendrocytes. J Immunol 181:1617–1621PubMedCrossRefGoogle Scholar
  141. 141.
    Scalfari A, Neuhaus A, Daumer M, Ebers GC, Muraro PA (2011) Age and disability accumulation in multiple sclerosis. Neurology 77:1246–1252PubMedPubMedCentralCrossRefGoogle Scholar
  142. 142.
    Scheikl T, Pugnolet B, Dalard C, Desbois S, Raison D, Yamazaki M, Saoudi A, Bauer J, Lassmann H, Hardin-Bouzet H, Liblau RS (2012) Cutting edge: neuronal recognition by CD8 T cells elicits central diabetes insipidus. J Immunol 188:4731–4735PubMedCrossRefGoogle Scholar
  143. 143.
    Scheld M, Rüther BJ, Große-Veldmann R, Ohl K, Tenbrock K, Dreymüller D, Fallier-Becker P, Zendedel A, Beyer C, Clarner T, Kipp M (2016) Neurodegeneration triggers peripheral immune cell recruitment into the forebrain. J Neurosci 36:1410–1415PubMedCrossRefGoogle Scholar
  144. 144.
    Schuh C, Wimmer I, Hametner S, Haider L, Van Dam AM, Liblau RS, Smith KJ, Probert L, Binder CJ, Bauer J, Bradl M, Mahad D, Lassmann H (2014) Oxidative injury in multiple scerosis is only partly reflected in experimental disease models. Acta Neuropathol 128:247–266PubMedPubMedCentralCrossRefGoogle Scholar
  145. 145.
    Segal BM, Constantinescu CS, Raychaudhuri A, Kim L, Fidelus-Gort R, Kasper LH (2008) Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study”. Lancet Neurol 7:796–804PubMedCrossRefGoogle Scholar
  146. 146.
    Seitelberger F, Jellinger K, Tschabitscher H (1958) Zur Genese der akuten Entmarkungsencephalitis. Wien Klein Wschr 70:453–459Google Scholar
  147. 147.
    Sepulveda M, Amangue T, Martinez-Hernandez E, Arrambide G, Sola-Valls N, Sabater L, Tellez N, Midaglia L, Arino H, Peschl P, Reindl M, Rovira A, Montalban X, Blanco Y, Dalmau J, Graus F, Saiz A (2016) Clinical spectrum associated with MOG autoimmunity in adults: significance of sharing rodent MOG epitopes. J Neurol 263:1349–1360PubMedCrossRefGoogle Scholar
  148. 148.
    Sharma R, Fischer MT, Bauer J, Felts PA, Smith KJ, Misu T, Fujihara K, Bradl M, Lassmann H (2010) Inflammation induced by innate immunity in the central nervous system leads to primary astrocyte dysfunction followed by demyelination. Acta Neuropathol 120:223–236PubMedPubMedCentralCrossRefGoogle Scholar
  149. 149.
    Shen S, Sandoval J, Swiss VA, Li J, Dupree J, Franklin RJ, Casacchia-Bonnefil P (2008) Age-dependent epigenetic control of differentiation inhibitors is critical for remyelination efficiency. Nat Neurosci 11:1024–1034PubMedPubMedCentralCrossRefGoogle Scholar
  150. 150.
    Singer BA (2016) Parental treatment of multiple sclerosis: the advent of monoclonal antbodies. Semin Neurol 36:140–147PubMedCrossRefGoogle Scholar
  151. 151.
    Soulika AM, Lee E, McCauley E, Miers L, Bannerman P, Pleasure D (2009) Initiation and progression of axonopathy in experimental autoimmune encephalomyelitis. J Neurosci 29:14965–14979PubMedPubMedCentralCrossRefGoogle Scholar
  152. 152.
    Steinman L, Zamvill SS (2016) Beginning of the end of two-stage theory purporting inflammation then degeneration explains pathogenesis of progressive multiple sclerosis. Curr Opin Neurol 29:340–344PubMedCrossRefGoogle Scholar
  153. 153.
    Stohlman SA, Hinton DR (2001) Viral induced demyelination. Brain Pathol 11:92–106PubMedCrossRefGoogle Scholar
  154. 154.
    Stohlman SA, Weiner LP (1981) Chronic central nervous system demyelination in mice after JHM virus infection. Neurology 31:38–44PubMedCrossRefGoogle Scholar
  155. 155.
    Storch MK, Bauer J, Linington C, Olsson T, Weissert R, Lassmann H (2006) Cortical demyelination can be modeled in specific rat models of autoimmune encephalomyelitis and is major histocompatability complex (MHC) haplotype-related. J Neuropathol Exp Neurol 65:1137–1142PubMedCrossRefGoogle Scholar
  156. 156.
    Storch MK, Stefferl A, Brehm U, Weissert R, Wallström E, Kerschensteiner M, Olsson T, Linington C, Lassmann H (1998) Autoimmunity to myelin oligodendrocyte glycoprotein in rats mimics the spectrum of multiple sclerosis pathology. Brain Pathol 8:681–694PubMedCrossRefGoogle Scholar
  157. 157.
    Stuart G, Krikorian KS (1928) The neuro-paralytic accidents of anti-rabies treatment. Ann Trop Med Parasitol 22:327–377CrossRefGoogle Scholar
  158. 158.
    Sun D, Whitaker JN, Huang Z, Liu D, Coleclough C, Wekerle H, Raine CS (2001) Myelin antigen-specific CD8+ T cells are encephalitogenic and produce severe disease in C57BL/6 mice. J Immunol 166:7579–7587PubMedCrossRefGoogle Scholar
  159. 159.
    Tabira T, Itoyama I, Kuroiwa Y (1984) The role of locally retained antigens in chronic relapsing experimental allergic encephalomyelitis in guinea pigs. Prog Clin Biol Res 146:43–48PubMedGoogle Scholar
  160. 160.
    Uchimura I, Shiraki H (1957) A contribution to the classification and the pathogenesis of demyelinating encephalomyelitis. J Neuropathol Exp Neurol 16:139–203PubMedCrossRefGoogle Scholar
  161. 161.
    Van Oosten BW, Lai M, Hodgkinson S, Barkhof F, Miller DH, Moseley IF, Thompson AJ, Rudge P, Mc Dougall A, McLeod JG, Ader HJ, Polman CH (1997) Treatment of multiple sclerosis with the monoclonal anti-CD4 antibody cM-T412: results of a randomized, double blind, placebo-controlled MR-monitored phase II trial. Neurology 49:351–357PubMedCrossRefGoogle Scholar
  162. 162.
    Vass K, Heininger K, Schäfer B, Linington C, Lassmann H (1992) Interferon-gamma potentiates antibody mediated demyelination in vivo. Ann Neurol 32:198–206PubMedCrossRefGoogle Scholar
  163. 163.
    Vogel DY, Vereyken EJ, Glim JE, Heijnen PD, Moeton M, van der Valk P, Amor S, Teunissen CE, van Horssen J, Dijkstra CD (2013) Macrophages in inflammatory multiple sclerosis lesions have an intermediate activation status. J Neuroinflamm 10:35CrossRefGoogle Scholar
  164. 164.
    Watanabe R, Wege H, ter Meulen V (1983) Adoptive transfer of EAE-like lesions from rats with coronavirus-induced demyelinating encephalomyelitis. Nature 305:150–153PubMedCrossRefGoogle Scholar
  165. 165.
    Weissert R, Wallström E, Storch MK, Stefferl A, Lorentzen J, Lassmann H, Linington C, Olsson T (1998) MHC haplotype dependent regulation of MOG-induced EAE in rats. J Clin Invest 102:1265–1273PubMedPubMedCentralCrossRefGoogle Scholar
  166. 166.
    Wekerle H, Kojima K, Lannes Vieira J, Lassmann H, Linington C (1994) Animal models. Ann Neurol Suppl S47–S53Google Scholar
  167. 167.
    Wekerle H, Linington C, Lassmann H, Meyermann R (1986) Cellular immune reactivity within the CNS. Trends Neurosci 9:271–277CrossRefGoogle Scholar
  168. 168.
    Wu GF, Perlman S (1999) Macrophage infiltration, but not apoptosis, is correlated with immune-mediated demyelination following murine infection with a neurotropic coronavirus. J Virol 73:8771–8780PubMedPubMedCentralGoogle Scholar
  169. 169.
    Zeka B, Hastermann M, Hochmeister S, Kögl N, Kaufmann N, Schanda K, Mader S, Misu T, Rommer P, Fujihara K, Illes Z, Leutmezer F, Sato DK, Nakashima I, Reindl M, Lassmann H, Bradl M (2015) Highly encephalitogenic aquaporin 4-specific T cells and NMO-IgG jointly orchestrate lesion location and tissue damage in the CNS. Acta Neuropathol 130:783–798PubMedPubMedCentralCrossRefGoogle Scholar

Copyright information

© The Author(s) 2016

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

Authors and Affiliations

  1. 1.Center for Brain ResearchMedical University of ViennaViennaAustria

Personalised recommendations